F01 | Transmembrane potential
GO:0051881
Transmembrane potential
Transmembrane potential
| Compound | Dose | Time | Species | Model | Method | Action | Result | Positive criterion | Reference |
|---|---|---|---|---|---|---|---|---|---|
| benzbromarone | 1 μmol/L | 1 hour | rat; Sprague–Dawley | hepatocytes | Measurement of mitochondrial membrane potential | decrease | Positive | p < 0.01 | 4 |
| benzbromarone | 4 μmol/L | 1 hour | rat; Sprague–Dawley | hepatocytes | Measurement of mitochondrial membrane potential | decrease | Positive | p < 0.01 | 4 |
| benzbromarone | 8 μmol/L | 1 hour | rat; Sprague–Dawley | hepatocytes | Measurement of mitochondrial membrane potential | decrease | Positive | p < 0.01 | 4 |
| benzbromarone | 20 μmol/L | 1 hour | rat; Sprague–Dawley | hepatocytes | Measurement of mitochondrial membrane potential | decrease | Positive | p < 0.01 | 4 |
| Amiodarone | 8 μmol/L | 1 hour | rat; Sprague–Dawley | hepatocytes | Measurement of mitochondrial membrane potential | decrease | Positive | p < 0.05 | 4 |
| Amiodarone | 20 μmol/L | 1 hour | rat; Sprague–Dawley | hepatocytes | Measurement of mitochondrial membrane potential | decrease | Positive | p < 0.01 | 4 |
| benzarone | 8 μmol/L | 1 hour | rat; Sprague–Dawley | hepatocytes | Measurement of mitochondrial membrane potential | decrease | Positive | p < 0.01 | 4 |
| benzarone | 20 μmol/L | 1 hour | rat; Sprague–Dawley | hepatocytes | Measurement of mitochondrial membrane potential | decrease | Positive | p < 0.01 | 4 |
| Amiodarone | 100 μmol/L | rat; Sprague–Dawley | hepatocytes | Measurement of oxygen uptake | affect | Positive | p < 0.01 | 4 | |
| benzarone | 50 μmol/L | rat; Sprague–Dawley | hepatocytes | Measurement of oxygen uptake | affect | Positive | p < 0.01 | 4 | |
| benzarone | 80 μmol/L | rat; Sprague–Dawley | hepatocytes | Measurement of oxygen uptake | affect | Positive | p < 0.01 | 4 | |
| benzarone | 100 μmol/L | rat; Sprague–Dawley | hepatocytes | Measurement of oxygen uptake | affect | Positive | p < 0.01 | 4 | |
| benzbromarone | 10 μmol/L | rat; Sprague–Dawley | hepatocytes | Measurement of oxygen uptake | affect | Positive | p < 0.01 | 4 | |
| benzbromarone | 20 μmol/L | rat; Sprague–Dawley | hepatocytes | Measurement of oxygen uptake | affect | Positive | p < 0.01 | 4 | |
| benzbromarone | 50 μmol/L | rat; Sprague–Dawley | hepatocytes | Measurement of oxygen uptake | affect | Positive | p < 0.01 | 4 | |
| benzbromarone | 80 μmol/L | rat; Sprague–Dawley | hepatocytes | Measurement of oxygen uptake | affect | Positive | p < 0.01 | 4 | |
| benzbromarone | 100 μmol/L | rat; Sprague–Dawley | hepatocytes | Measurement of oxygen uptake | affect | Positive | p < 0.01 | 4 | |
| Diclofenac | 12.5 μmol/L | 10 minutes | rat | liver mitochondria | Assessment of MPT | increase | Positive | not mentioned | 6 |
| Diclofenac | 25 μmol/L | 10 minutes | rat | liver mitochondria | Assessment of MPT | increase | Positive | not mentioned | 6 |
| Diclofenac | 50 μmol/L | 10 minutes | rat | liver mitochondria | Assessment of MPT | increase | Positive | not mentioned | 6 |
| Diclofenac | 100 μmol/L | 10 minutes | rat | liver mitochondria | Assessment of MPT | increase | Positive | not mentioned | 6 |
| Diclofenac | 50 μmol/L | 3 minutes | rat | liver mitochondria | Assessment of Mitochondrial Membrane Potential; incubated in the presence of Ca2+ | decrease | Positive | p < 0.01 | 6 |
| Cyclosporin A | 1 μmol/L | 3 minutes | rat | liver mitochondria | Assessment of Mitochondrial Membrane Potential; coincubated with diclofenac | decrease | Positive | p < 0.05 | 6 |
| DPPD | 1 μmol/L | 3 minutes | rat | liver mitochondria | Assessment of Mitochondrial Membrane Potential; coincubated with diclofenac | decrease | Positive | p < 0.05 | 6 |
| Diclofenac | 250 μmol/L | 24 hours | rat | hepatocytes | Assessment of Mitochondrial Membrane Potential | decrease | Positive | p < 0.01 | 6 |
| Diclofenac | 500 μmol/L | 24 hours | rat | hepatocytes | Assessment of Mitochondrial Membrane Potential | decrease | Positive | p < 0.01 | 6 |
| Metformin | 1 mM | 24 hours | human | hepatocytes | Measurement of mitochondrial membrane potential | decrease | Positive | 15 | |
| Metformin | 2 mM | 24 hours | human | hepatocytes | Measurement of mitochondrial membrane potential | decrease | Positive | 15 | |
| buformin | 75 μM | 24 hours | human | hepatocytes | Measurement of mitochondrial membrane potential | decrease | Positive | 15 | |
| Phenformin | 12.5 μM | 24 hours | human | hepatocytes | Measurement of mitochondrial membrane potential | decrease | Positive | 15 | |
| Perhexiline | 200 μM | mouse; Crl/CD-l(1CR)BR Swiss | liver mitochondria | Measurement of mitochondrial membrane potential | decrease | Positive | 193 | ||
| 2,4-dinitrophenol | increase | Positive | 24 | ||||||
| CCCP | increase | Positive | 27 | ||||||
| Salicylic acid | increase | Positive | 31 | ||||||
| benzbromarone | increase | Positive | 35 | ||||||
| Entacapone | increase | Positive | 35 | ||||||
| Menadione | increase | Positive | 35 | ||||||
| Nimesulide | increase | Positive | 35 | ||||||
| Primaquine | increase | Positive | 35 | ||||||
| Tolcapone | increase | Positive | 35 | ||||||
| Troglitazone | increase | Positive | 35 | ||||||
| 2,4-dinitrophenol | increase | Positive | 35 | ||||||
| CCCP | increase | Positive | 35 | ||||||
| FCCP | increase | Positive | 35 | ||||||
| Papaverine | increase | Positive | 35 | ||||||
| alpidem | increase | Positive | 36 | ||||||
| Diclofenac | increase | Positive | 39 | ||||||
| Diflunisal | increase | Positive | 40 | ||||||
| Hexachlorophene | increase | Positive | 42 | ||||||
| Ketoconazole | increase | Positive | 36 | ||||||
| lovastatin | increase | Positive | 36 | ||||||
| Nimesulide | increase | Positive | 36 | ||||||
| Nitrofurantoin | increase | Positive | 36 | ||||||
| Rosiglitazone | increase | Positive | 7 | ||||||
| sitaxsentan | increase | Positive | 44 | ||||||
| Sulindac | increase | Positive | 45 | ||||||
| Tamoxifen | increase | Positive | 46 | ||||||
| Troglitazone | increase | Positive | 7 | ||||||
| erlotinib | increase | Positive | 36 | ||||||
| imipramine | increase | Positive | 36 | ||||||
| Menadione | increase | Positive | 47 | ||||||
| Thioridazine | increase | Positive | 49 | ||||||
| pentamidine | increase | Positive | 51 | ||||||
| para-nonylphenol | rat | isolated liver mitochondria | measurements of mitochondrial respiration; RST inhibition assay, RST uncoupling assay; IC 50ratio of glucose/galactose assay | increase | Positive | 53 | |||
| ezlopitant | rat | isolated liver mitochondria | measurements of mitochondrial respiration; RST inhibition assay, RST uncoupling assay; IC 50ratio of glucose/galactose assay | increase | Positive | 53 | |||
| procarbazine | rat | isolated liver mitochondria | measurements of mitochondrial respiration; RST inhibition assay, RST uncoupling assay; IC 50ratio of glucose/galactose assay | increase | Positive | 53 | |||
| rifabutin | rat | isolated liver mitochondria | measurements of mitochondrial respiration; RST inhibition assay, RST uncoupling assay; IC 50ratio of glucose/galactose assay | increase | Positive | 53 | |||
| ritolukast | rat | isolated liver mitochondria | measurements of mitochondrial respiration; RST inhibition assay, RST uncoupling assay; IC 50ratio of glucose/galactose assay | increase | Positive | 53 | |||
| Trifluoperazine | rat | isolated liver mitochondria | measurements of mitochondrial respiration; RST inhibition assay, RST uncoupling assay; IC 50ratio of glucose/galactose assay | increase | Positive | 53 | |||
| crizotinib | rat | isolated liver mitochondria | measurements of mitochondrial respiration; RST inhibition assay, RST uncoupling assay; IC 50ratio of glucose/galactose assay | increase | Positive | 53 | |||
| tenidap | rat | isolated liver mitochondria | measurements of mitochondrial respiration; RST inhibition assay, RST uncoupling assay; IC 50ratio of glucose/galactose assay | increase | Positive | 53 | |||
| benztropine mesylate | rat | isolated liver mitochondria | measurements of mitochondrial respiration; RST inhibition assay, RST uncoupling assay; IC 50ratio of glucose/galactose assay | increase | Positive | 53 | |||
| clemastine | rat | isolated liver mitochondria | measurements of mitochondrial respiration; RST inhibition assay, RST uncoupling assay; IC 50ratio of glucose/galactose assay | increase | Positive | 53 | |||
| darifenacin | rat | isolated liver mitochondria | measurements of mitochondrial respiration; RST inhibition assay, RST uncoupling assay; IC 50ratio of glucose/galactose assay | increase | Positive | 53 | |||
| protriptyline | rat | isolated liver mitochondria | measurements of mitochondrial respiration; RST inhibition assay, RST uncoupling assay; IC 50ratio of glucose/galactose assay | increase | Positive | 53 | |||
| tolterodine | rat | isolated liver mitochondria | measurements of mitochondrial respiration; RST inhibition assay, RST uncoupling assay; IC 50ratio of glucose/galactose assay | increase | Positive | 53 | |||
| chenodeoxycholic acid | rat | isolated liver mitochondria | increase | Positive | 55 | ||||
| Etodolac | isolated mitochondria | increase | Positive | 56 | |||||
| Bupivacaine | decrease | Positive | 61 | ||||||
| Bupivacaine | decrease | Positive | 61 | ||||||
| aristolochic acid | isolated kidney mitochondria | increase | Positive | 64 | |||||
| Indomethacin | rat | isolated liver mitochondria | increase | Positive | 65 | ||||
| ochratoxin a | rat | isolated liver mitochondria | increase | Positive | 66 | ||||
| Paraquat | increase | Positive | 67 | ||||||
| Paraquat | increase | Positive | 67 | ||||||
| Mersalyl | 130 μM | bovine | heart MF0, proton conductivity | affect | Positive | 70% inhibition | 170 | ||
| (1,1,3,3-tetramethylbutyl)phenol | 2.85±0.86 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| (1'-ethyl-6,7-dihydro-5h-spiro[furo[2,3-f]indole-3,4'-piperidin]-5-yl)[2'-methyl-4'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-4-yl]methanone hydrochloride | 6.09±2.54 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| (2-ethyl-4-{[(4-{[4-(4-methoxyphenyl)piperazin-1-yl]methyl}-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl)methyl]sulfanyl}phenoxy)acetic acid | 25.29±5.81 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| (2-nitro-1-propenyl)benzene | 38.57±15.32 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| (5-chloro-2-hydroxyphenyl)phenylmethanone | 29.09±3.36 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| (5s,8s)-5-(3,4-dichlorophenyl)-8-(methylamino)-5,6,7,8-tetrahydronaphthalene-2-sulfonamide | 8.31±1.43 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| (9z)-octadec-9-enamide | 41.61±7.16 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| (acryloyloxy)(tributyl)stannane | 0.19±0.11 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| (n-6)-methyladenine | 5.98±5.84 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1-(2,3,8,8-tetramethyl-1,2,3,4,5,6,7,8-octahydronaphthalen-2-yl)ethanone | 27.31±20.44 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1-(3,5,5,6,8,8-hexamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)ethanone | 30.64±18.87 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1,1,1-trichloropropanone | 1.22±0.56 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1,1,2-trimethyl-1h-benzo[e]indole | 23.42±4.03 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1,1':3',1''-terphenyl | 47.88±14.29 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1,2,5,6,9,10-hexabromocyclododecane | 6.93±1.95 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1,2-benzisothiazolin-3-one | 38.57±13.65 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1,2-phenylenediamine | 3.90±3.61 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1,2-phenylenediamine dihydrochloride | 0.44±0.20 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1,3,5-tris(4-tert-butyl-3-hydroxy-2,6-dimethylbenzyl)-1,3,5-triazinane-2,4,6-trione | 12.20±2.84 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1,3-didecyl-2-methylimidazolium chloride | 3.86±4.19 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1,3-diiminobenz(f)isoindoline | 11.08±7.81 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1,3-diphenyl-1,3-propanedione | 11.68±1.35 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1,4-benzenediamine | 3.28±0.42 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1,4-diaminoanthraquinone | 0.03±0.01 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1,4-dihydroxyanthracene-9,10-dione | 5.24±3.43 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1,4-naphthalenediamine | 0.20±0.08 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1,5-naphthalenediamine | 17.00±19.61 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1,8-dihydroxy-4,5-dinitroanthraquinone | 0.07±0.04 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 10-chloro-9-anthraldehyde | 13.87±7.82 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| Mito-4509 | 37.81±13.89 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 17alpha-ethinylestradiol | 19.12±5.99 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1-amino-2,4-dibromoanthraquinone | 2.78±3.75 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1-amino-2-methylanthraquinone | 0.64±0.08 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1-benzyl-1-{[3-(4-chlorophenyl)-5-methyl-1-benzofuran-2-yl]methyl}-3-(2,4,6-trifluorophenyl)urea | 21.01±2.43 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1-decyl-3-methylimidazolium tetrafluoroborate | 3.87±16.67 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1-decyl-3-methylimidazolium trifluoromethanesulfonate | 1.67±2.71 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1-dodecyl-3-methylimidazolium hexafluorophosphate | 3.71±8.52 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1-fluoro-2,4-dinitrobenzene | 3.71±0.60 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1h,3h-naphtho(1,8-cd)pyran-1,3-dione | 3.89±1.12 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1h-benzo[de]isoquinoline-1,3(2h)-dione | 8.31±3.47 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1h-indole-2-carboxamide, n-[(3r)-1-(2-fluorophenyl)-3,4,6,7-tetrahydro-4-oxopyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl]- | 8.41±0.00 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1-hydroxypyrene | 4.67±1.95 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1-isocyanato-3-(trifluoromethyl)benzene | 3.28±1.13 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1-methyl-3-octylimidazolium hexafluorophosphate | 8.23±5.05 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1-methyl-3-octylimidazolium tetrafluoroborate | 5.66±5.82 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1-methyl-3-octylimidazolium trifluoromethanesulfonate | 8.38±4.29 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1-methylpyrene | 43.23±4.99 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1-naphthol | 31.04±5.96 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1-nitronaphthalene | 59.74±7.06 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1-nitropyrene | 2.01±2.06 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| Edaravone | 31.75±4.28 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1-trans-delta-9-tetrahydrocannabinol | 4.99±1.66 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-(4-hydroxybenzyl)phenol | 27.47±1.92 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-(butan-2-yl)phenol | 49.48±9.45 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-(thiocyanomethylthio)benzothiazole | 33.08±4.58 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,2',4,4',5-pentabromodiphenyl ether | 8.00±3.19 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,2',6,6'-tetrachlorobisphenol a | 4.86±3.13 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,2'4,4'-tetrabromodiphenyl ether | 22.56±5.18 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane | 8.78±1.43 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,2-bis[(benzoyloxy)methyl]dibenzoate propanediol | 4.32±8.63 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,2'-dichlorobiphenyl | 31.09±12.28 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,2'-dihydroxy-4,4'-dimethoxybenzophenone | 7.75±1.80 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,2'-dihydroxy-4-methoxybenzophenone | 9.89±1.04 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,2'-methylenebis(4-methyl-6-tert-butylphenol) | 1.35±0.26 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,2'-methylenebis(ethyl-6-tert-butylphenol) | 1.22±0.73 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,3',4,4'-tetrahydroxybenzophenone | 7.39±7.14 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,3,4,5-tetrachlorophenol | 4.93±2.04 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,3,4-trichlorophenol | 5.23±1.52 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,3,5,6-tetrachlorophenol | 6.42±2.38 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,3,5-trichlorophenol | 5.80±1.05 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,4,5-trichlorophenol sodium salt | 5.05±2.09 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,4,6-trinitro-1,3-dimethyl-5-tert-butylbenzene | 20.09±6.09 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,4-bis(1-methyl-1-phenylethyl)phenol | 3.49±1.51 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,4-diaminoanisole sulfate | 2.51±1.16 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,4-diaminophenol dihydrochloride | 3.77±1.06 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,4-dichloro-3,5-dimethylphenol | 5.88±4.85 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,4-diisopropylphenol | 17.23±1.99 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,4-di-tert-butylphenol | 3.50±0.73 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,5-bis(2-methylbutan-2-yl)benzene-1,4-diol | 6.86±3.17 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,5-di-tert-butylbenzene-1,4-diol | 7.41±1.27 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,6-bis-(1,1-dimethylethyl)-2,5-cyclohexadiene-1,4-dione | 18.60±12.40 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,6-di(butan-2-yl)phenol | 13.69±3.19 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,6-diaminopyridine | 31.28±10.35 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,6-di-tert-butyl-4-nitrophenol | 0.17±0.05 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,6-toluenediamine | 15.70±10.03 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 24r,25-dihydroxyvitamin d3 | 13.02±2.17 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-Acetylaminofluorene | 36.27±10.50 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-amino-4-(p-nitrophenyl)thiazole | 3.90±1.78 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-amino-4,6-dinitrophenol | 4.18±2.00 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-amino-4-chloro-5-nitrophenol | 21.51±2.48 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-amino-4-chlorobenzothiazole | 29.57±5.09 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-amino-5-nitrophenol | 27.40±14.08 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-amino-6-nitrobenzothiazole | 12.69±10.45 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-aminoanthracene | 4.71±1.92 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-aminoanthraquinone | 0.51±0.29 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-chloro-4-phenylphenol | 15.36±7.86 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-dodecylisoquinolinium tosylate | 3.53±0.50 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-hydrazino-4-(4-aminophenyl) thiazole | 0.06±0.02 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-hydrazino-4-(4-nitrophenyl)thiazole | 1.60±0.29 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-hydrazino-4-phenylthiazole | 2.32±0.79 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-hydroxyanthraquinone | 3.31±1.38 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-isovaleryl-1,3-indanedione | 5.24±0.90 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-methyl-1-nitroanthraquinone | 1.34±0.15 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-methylanthraquinone | 6.33±1.15 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-naphthalenesulfonic acid, 7-amino-4-hydroxy- | 27.33±3.73 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-naphthalenol | 50.10±16.03 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-nitro-1,4-phenylenediamine | 7.07±6.53 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-nitrofluorene | 12.19±0.86 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-pentylfuran | 42.19±2.81 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-phenylphenol | 17.90±1.41 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-propenal,3,3-diphenyl- | 41.19±19.34 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-tert-butyl-4-ethylphenol | 11.30±2.60 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-tert-butyl-4-methoxyphenol | 25.29±1.71 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-tert-butyl-5-methylphenol | 23.48±2.85 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 3-(5,5,6-trimethylbicyclo[2.2.1]hept-2-yl)cyclohexanol | 31.84±17.54 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 3,3',4,4'-tetraaminobiphenyl tetrahydrochloride | 0.34±0.26 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 3,3',5,5'-tetraiodothyroacetic acid | 45.79±2.99 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 3,3'-diaminobenzidine | 13.69±14.86 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 3,3'-dimethylbisphenol a | 8.88±3.37 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 3,3φ,5,5φ-tetrabromobisphenol a | 13.23±12.24 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 3,4,5-trichlorophenol | 3.80±1.74 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 3,4-dichlorophenol | 9.18±2.63 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 3,5-dichlorophenol | 9.79±0.00 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 3,5-dichlorosalicyl-3,4-dichloroanilide | 0.22±0.09 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 3-acetylphenanthrene | 36.89±13.68 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 3-amino-9-ethylcarbazole hydrochloride | 35.36±24.49 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 3-hydroxybenzophenone | 27.72±0.00 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 3-hydroxy-n-(3-nitrophenyl)naphthalene-2-carboxamide | 0.24±0.09 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 3-hydroxy-n-phenylaniline | 28.48±6.04 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 3-methylbenzene-1,2-diamine | 21.74±3.65 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 3-methylcholanthrene | 17.26±13.23 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 3-methyl-n-phenylaniline | 48.56±5.61 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-(1,1,3,3-tetramethylbutyl)phenol | 4.25±0.92 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-(2-methylbutan-2-yl)phenol | 22.71±3.07 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-(3-phenylpropyl)pyridine | 16.58±6.74 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-(benzyloxyl)phenol | 18.46±1.51 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-(butan-2-yl)phenol | 31.98±3.64 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4,4,4-trifluoro-1-phenyl-1,3-butanedione | 20.37±6.17 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4,4'-diaminoazobenzene | 10.45±3.59 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4,4'-diaminobenzanilide | 3.72±2.85 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4,4'-dichlorodiphenyl sulfone | 21.27±6.06 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4,4'-dinitrodiphenylurea | 0.46±0.06 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4,4'-methylenebis(2-chloroaniline) | 49.14±17.00 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4,4'-sulfonylbis[2-(prop-2-en-1-yl)phenol] | 44.97±17.92 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4,4'-thiobis(6-tert-butyl-m-cresol) | 1.86±1.18 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4,4'-thiodiphenol | 21.08±2.70 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4,6-dichloro-1,3-benzenediol | 9.55±2.74 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4,6-di-tert-butyl-m-cresol | 2.25±1.49 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-amino-2,6-dichlorophenol | 17.23±13.38 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-amino-2-nitrophenol | 15.42±10.56 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-amino-4φ-hydroxy-3-methyldiphenylamine | 7.66±0.88 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-benzylphenol | 15.94±3.38 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-chloro-1,2-diaminobenzene | 2.38±1.60 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-chloro-2-cyclopentylphenol | 5.66±1.93 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-chloro-3,5-dimethylphenol | 21.00±0.00 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-chlorophenyl isocyanate | 0.27±0.11 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-cumylphenol | 3.70±0.82 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4'-demethylepipodophyllotoxin | 2.66±3.92 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-dodecylphenol | 3.18±0.58 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-hexyl-4'-cyanobiphenyl | 42.53±15.42 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-hydroxybenzophenone | 41.31±18.12 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-methyl-2,6-dinitrophenol | 26.55±4.57 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-nitroanthranilic acid | 38.57±17.22 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-nitro-n-phenylaniline | 7.43±6.54 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-nitrosophenol | 4.71±2.31 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-octyloxybenzoic acid | 39.63±31.34 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-octylphenol | 8.77±2.96 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-phenoxyphenol | 27.97±10.62 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-styrylpyridine | 11.22±5.54 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-tert-butylcatechol | 34.27±14.96 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-tert-butylphenyl salicylate | 28.37±3.64 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 5,7-dichloro-8-hydroxy-2-methylquinoline | 11.01±2.00 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 5alpha-dihydrotestosterone | 13.30±6.16 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 5hpp-33 | 2.09±0.87 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| Busulfan | 14.43±5.99 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 5-nitroacenaphthene | 34.38±20.44 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 6-hydroxy-2-naphthyl disulfide | 33.74±3.64 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 6-nitrobenzimidazole | 36.41±10.82 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 6-nitroquinoline | 30.73±11.46 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 9,10-dihydrobenzo[a]pyren-7(8h)-one | 9.81±2.08 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 9-aminoacridine, monohydrochloride, monohydrate | 13.80±1.75 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 9-anthracenemethanol | 34.48±11.46 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 9-cyanoanthracene | 6.85±18.05 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 9-nitroanthracene | 21.44±12.82 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 9-phenanthrol | 1.22±0.56 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| acenocoumarol | 8.36±1.07 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| acetaldehyde | 18.02±6.38 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| aclarubicin hydrochloride | 3.15±2.82 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| acriflavine hydrochloride | 0.94±0.44 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| Albendazole | 9.35±1.83 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| aldrin | 31.20±7.21 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| alizarin | 11.01±1.41 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| allylestrenol | 12.83±3.68 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| aloe-emodin | 1.79±1.54 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| alpha-1,2,3,4,5,6-hexachlorocyclohexane | 49.00±6.35 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| alpha-amylcinnamyl alcohol | 38.11±17.40 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| ambazone | 5.60±3.23 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| ami-193 | 5.82±3.05 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| aminoquinuride dihydrochloride | 25.01±4.09 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| amorolfine | 21.61±3.47 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| amsacrine hydrochloride | 10.34±2.45 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| amylmetacresol | 11.17±0.65 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| anthrone | 21.84±9.90 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| apigenin | 1.61±0.00 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| aranidipine | 12.83±3.68 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| aroclor 1260 | 21.47±2.75 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| arotinolol hydrochloride | 17.04±3.45 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| axitinib | 3.76±2.80 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| barban | 22.54±4.10 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| bardoxolone methyl | 5.11±1.27 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| barium bis(2-ethylhexanoate) | 15.36±10.31 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| barium chloride | 16.58±8.50 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| basic blue 7 | 0.02±0.03 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| bazedoxifene | 11.01±0.75 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| beclazone | 23.71±2.74 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| benzbromarone | 7.22±1.24 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| benzidine | 24.34±4.50 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| benziodarone | 2.98±0.63 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| benzobarbital | 24.07±5.12 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| benzoic acid, 2-[(4-chloro-3-methylphenyl)amino]- | 12.83±0.84 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| benzyldimethyltetradecylammonium chloride dihydrate | 16.40±4.28 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| benzyldodecyldimethylammonium bromide | 11.44±4.34 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| benzylhydrazine dihydrochloride | 27.81±3.21 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| berberine chloride | 2.03±1.29 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| betamethasone dipropionate | 25.60±1.67 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| bexarotene | 16.49±3.95 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| bis(tributyltin)oxide | 0.09±0.02 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| bisacodyl | 14.82±3.63 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| Bisphenol A | 13.97±6.29 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| bisphenol a glycidyl methacrylate | 12.20±11.86 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| bisphenol af | 5.44±1.42 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| bisphenol b | 10.66±2.48 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| bisphenol e | 27.64±1.80 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| bisphenol z | 22.19±5.51 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| bithionol | 0.66±0.52 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| bosutinib | 0.75±0.48 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| bromadiolone | 16.67±1.13 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| bromociclen | 33.18±3.47 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| bromocriptine | 11.44±1.58 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| bromocriptine mesylate | 11.19±2.78 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| bromofenoxim | 1.08±0.25 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| bromofos | 7.70±1.63 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| bromoxynil octanoate | 15.29±5.08 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| broquinaldol | 26.60±4.00 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| bryostatin 1 | 0.01±0.01 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| buclizine dihydrochloride | 32.23±2.10 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| butylparaben | 19.00±0.00 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| c.i. 1040 | 8.10±1.39 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| c.i. basic orange 2 | 7.53±5.61 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| c.i. basic red 9 monohydrochloride | 0.08±0.02 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| c.i. basic violet 14 | 0.18±0.16 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| c.i. disperse blue 27 | 2.34±0.87 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| c.i. solvent yellow 14 | 5.84±2.06 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| calcifediol | 5.82±0.47 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| calcipotriene | 25.98±3.89 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| calcitriol | 14.06±4.15 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| candesartan cilexetil | 15.94±4.62 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| cannabinol | 1.68±0.00 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| cantharidin | 0.15±0.08 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| CCCP | 0.15±0.04 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| carminomycin | 1.25±0.73 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| chlorfenapyr | 0.07±0.04 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| chlorfenethol | 26.28±7.53 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| chlorfenson | 38.83±25.41 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| chlorfluazuron | 8.93±4.57 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| chlorophacinone | 0.64±0.25 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| chloropropylate | 26.28±3.64 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| chloroxine | 10.59±1.22 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| chromomycin | 12.35±0.84 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| chrysarobin | 22.82±3.93 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| chrysin | 5.05±2.76 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| ciclesonide | 7.91±1.38 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| Ciglitazone | 8.22±1.60 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| cilnidipine | 12.53±1.78 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| cinalukast | 28.81±1.17 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| clobetasol | 14.40±3.67 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| clobetasol propionate | 24.64±1.67 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| cloflucarban | 0.60±0.00 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| clofoctol | 1.64±0.13 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| clonixin | 19.86±6.75 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| cloxyquin | 16.79±5.94 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| coumatetralyl | 13.69±4.84 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| cresyl diphenyl phosphate | 2.38±2.32 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| curcumin | 1.31±1.03 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| cybutryne | 20.87±13.91 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| cyclododecanol | 48.78±3.84 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| cyhalothrin | 33.62±5.79 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| d&c yellow 11 | 0.38±0.13 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| danthron | 4.66±1.19 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| dantrolene sodium | 4.35±1.73 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| darbufelone mesylate | 11.74±2.02 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| deltamethrin | 45.88±17.92 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| deslanoside | 1.84±0.23 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| desogestrel | 22.29±2.11 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| devazepide | 12.53±5.62 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| dexamethasone valerate | 12.06±4.39 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| diacerein | 20.64±8.26 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| dianiline | 18.40±5.73 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| dichlofluanid | 5.24±1.99 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| dichlorodiphenylsilane | 12.96±9.66 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| diclazuril | 11.17±2.79 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| dicofol | 9.69±3.51 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| N,N'-dicyclohexylcarbodiimide | 0.30±0.20 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| dienestrol | 10.93±1.88 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| Diethylstilbestrol | 9.76±6.25 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| diethylstilbestrol dipropionate | 10.46±2.66 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| diflorasone diacetate | 28.73±1.87 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| digitoxin | 0.16±0.05 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| digoxin | 0.52±0.09 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| dihydrotachysterol | 32.71±1.32 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| dinex | 0.28±0.34 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| diniconazole | 12.18±3.53 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| dinobuton | 4.33±1.24 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| dinocap | 0.34±0.30 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| dinoterb | 0.48±0.00 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| diphenan | 22.29±4.67 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| diphenoxylate hydrochloride | 20.65±1.19 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| diphenylcyclopropenone | 25.60±1.67 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| diphenylurea | 1.60±0.74 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| disperse red 82 | 8.00±1.45 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| dithiazanine chloride | 0.27±0.82 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| dithiazanine iodide | 0.10±0.15 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| docetaxel | 14.96±29.77 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| dodecyl gallate | 4.75±1.81 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| dodecylparaben | 4.19±1.07 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| dodecylphenol | 3.10±1.22 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| doramapimod;bibr-796? | 21.13±5.52 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| doramectin | 11.88±0.00 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| ebselen | 23.16±0.93 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| emodin | 1.33±0.78 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| endosulfan sulfate | 15.96±2.05 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| endrin | 23.52±7.96 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| enterolactone | 9.99±5.02 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| eprinomectin (b1a, b1b mixture) | 4.22±0.90 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| equilin | 24.34±4.60 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| ergotamine d-tartrate | 7.55±1.06 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| estradiol acetate | 9.08±0.59 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| ethacridine lactate hydrate | 3.22±0.55 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| ethalfluralin | 43.28±17.60 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| ethanol, 2,2'-((1-methylethylidene)bis((2,6-dibromo-4,1-phenylene)oxy))bis- | 6.21±0.42 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| ethoxazene | 2.70±1.13 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| ethyl linolenate | 49.65±36.02 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| ethynodiol diacetate | 15.40±0.84 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| etocarlide | 17.04±6.52 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| everolimus | 19.86±2.83 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| exalamide | 9.81±3.00 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| ezetimibe | 25.60±3.54 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| famoxadone | 4.19±1.07 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| fenamidone | 43.28±17.10 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| fenarimol | 42.59±21.91 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| fenchlorphos | 13.62±2.52 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| fendiline hydrochloride | 10.34±1.55 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| fenhexamid | 8.31±1.15 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| fenobam | 25.85±1.87 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| fenretinide | 3.40±0.76 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| fentiazac | 27.43±2.92 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| fenticlor | 2.15±0.36 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| fenvalerate | 32.06±0.00 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| flopropione | 18.83±6.83 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| fluazuron | 3.96±2.31 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| flubendiamide | 18.72±2.59 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| flucythrinate | 35.72±20.02 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| Flufenamic Acid | 36.64±1.87 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| flunixin meglumine | 9.02±0.00 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| fluorodifen | 27.31±25.06 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| fluorosalan | 0.24±0.09 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| fluoxastrobin | 45.79±15.00 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| fluticasone propionate | 9.02±1.71 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| fluvastatin | 27.64±1.87 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| folpet | 8.25±0.54 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| forchlorfenuron | 0.45±0.13 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| formononetin | 13.17±4.88 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| fulvestrant | 5.86±0.82 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| geliomycin | 0.52±0.04 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| genistein | 6.34±0.77 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| gentian violet | 0.08±0.04 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| glycyrrhetinic acid | 40.10±9.34 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| gramicidin | 0.51±0.42 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| halobetasol propionate | 15.18±5.52 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| heptachlor | 39.40±17.92 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| Hexachlorophene | 0.70±0.46 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| hydroxystilbamidine bis(methanesulfonate) | 2.81±0.90 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| idarubicin hydrochloride | 6.83±1.46 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| idazoxan | 20.64±7.46 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| indole-3-pyruvic acid | 28.92±16.69 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| indoxacarb | 12.73±3.65 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| iodophthalein | 5.31±1.76 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| iodophthalein sodium | 10.75±3.91 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| isobutylparaben | 14.21±1.82 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| isodrin | 43.28±15.32 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| isoxaben | 26.32±5.75 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| isoxicam | 5.18±2.90 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| israpafant | 21.96±1.49 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| kaempferol | 2.56±3.04 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| kepone | 0.93±0.65 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| Ketoconazole | 10.81±3.25 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| lambda-cyhalothrin | 24.35±1.59 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| lanatoside a | 0.43±0.04 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| lanatoside b | 1.10±0.20 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| lanatoside c | 0.78±0.14 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| lapachol | 26.12±1.70 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| lasalocid sodium | 1.14±0.07 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| lercanidipine hydrochloride | 6.53±0.53 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| lestaurtinib | 4.80±0.97 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| lopinavir | 32.71±1.32 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| lornoxicam | 9.44±1.09 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| lufenuron | 7.65±0.70 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| lynestrenol | 16.63±2.15 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| lysergide | 9.03±1.87 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| malachite green oxalate | 2.10±1.87 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| malotilate | 14.96±1.99 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| manidipine | 12.15±6.82 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| Mebendazole | 2.45±0.34 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| Meloxicam | 14.47±0.00 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| mepartricin | 23.16±6.59 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| mepronil | 40.86±19.18 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| mesotrione | 17.97±11.96 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| metanixin | 25.98±2.11 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| methfuroxam | 25.78±1.71 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| methisazone | 5.82±1.38 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| Methoxychlor | 26.28±8.69 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| methyl 2,4-dihydroxy-3,6-dimethylbenzoate | 15.96±6.62 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| methyl triclosan | 25.53±1.67 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| methyl violet | 0.07±0.03 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| methyldigoxin | 0.73±0.09 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| Methylene Blue | 2.88±1.33 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| methylene blue trihydrate | 1.31±0.79 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| methylsilanetriyl triacetate | 29.07±16.38 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| methyltrioctylammonium trifluoromethanesulfonate | 2.16±0.72 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| metochalcone | 18.18±10.11 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| mgk-264 | 15.36±10.52 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| mifepristone | 16.13±32.54 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| miripirium chloride | 16.40±4.01 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| mk-2206 | 17.78±7.38 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| mometasone furoate | 11.80±0.80 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| montelukast sodium | 32.71±1.32 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| n,n-diethylbenzene-1,4-diamine | 49.89±3.51 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| n,n-dimethyl-p-phenylenediamine | 9.10±0.59 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| n,nφ-diethylcarbanilide | 21.69±38.23 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| n-benzyl-6-ethoxy-4-oxo-1,4-dihydro-1,5-naphthyridine-3-carboxamide | 14.78±9.66 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| n-cyclohexyl-4-methyl benzenesulfonamide | 36.15±20.97 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| nelfinavir mesylate | 11.88±6.92 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| Niclosamide | 0.03±0.01 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| niflumic acid | 13.02±2.17 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| nifuroxazide | 1.57±0.30 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| Nimesulide | 3.87±0.23 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| ninhydrin | 32.00±9.69 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| Nitazoxanide | 1.04±0.96 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| Nitrofurantoin | 26.31±6.35 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| nitrovin | 3.27±0.57 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| nitroxoline | 9.22±2.41 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| n-methyl-n,n-dioctyloctan-1-aminium chloride | 2.73±0.32 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| nocodazole | 3.53±1.63 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| nonylparaben | 4.43±0.30 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| norelgestromin | 13.53±6.64 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| noristerat | 9.81±1.78 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| n-phenyl-1,4-benzenediamine hydrochloride | 5.82±6.96 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| o,p'-ddd | 19.83±0.94 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| o,p'-ddt | 23.98±12.11 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| olvanil | 13.53±1.90 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| osalmid | 6.68±0.77 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| ouabain | 0.18±0.00 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| oxyphenisatin acetate | 5.49±4.60 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| p,p'-ddd | 15.19±8.82 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| p,p'-dde | 25.60±1.71 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| p,p'-ddt | 24.26±2.74 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| palmatine chloride hydrate | 22.74±5.23 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| paricalcitol | 8.91±1.56 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| p-benzoquinone dioxime | 43.30±14.86 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| penfluridol | 33.49±0.00 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,2',4,4',5-pentabromodiphenyl ether | 15.46±7.01 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| pentabromophenol | 3.46±0.99 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| Pentachlorophenol | 3.09±0.60 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| pentylparaben | 8.74±1.65 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| perfluorooctanesulfonamide | 2.43±0.81 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| phenazopyridine hydrochloride | 15.72±3.45 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| phenmedipham | 4.41±2.02 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| phenol, 4,4'-butylidenebis[2-(1,1-dimethylethyl)-5-methyl- | 5.51±1.58 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| phenol, 4-methyl-, reaction products with dicyclopentadiene and isobutylene | 15.55±8.56 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| phenolphthalein | 42.78±2.74 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| phenoxybenzamine hydrochloride | 48.80±9.17 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| phenyl isothiocyanate | 43.01±14.76 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| phloretin | 4.26±1.22 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| picoxystrobin | 9.31±2.67 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| picropodophyllin | 0.14±0.02 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| pinacyanol | 0.01±0.00 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| pirarubicin | 0.60±0.46 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| pirenoxine sodium | 21.13±17.82 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| Piroxicam | 8.21±1.71 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| polyethylene glycol (9z)-9-octadecenyl ether | 7.50±18.45 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| polyoxyethylene(10)nonylphenyl ether | 10.20±6.92 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| p-phenylazophenol | 4.06±1.23 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| prodiamine | 4.84±0.56 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| profenofos | 2.54±1.84 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| proflavin hemisulfate | 3.22±0.82 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| proflavin hydrochloride | 1.66±0.63 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| profluralin | 21.69±8.04 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| propan-2-yl (2r,4s)-4-{acetyl[3,5-bis(trifluoromethyl)benzyl]amino}-2-ethyl-6-(trifluoromethyl)-3,4-dihydroquinoline-1(2h)-carboxylate | 5.66±1.72 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| propyl gallate | 42.29±3.93 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| propylparaben | 38.60±1.67 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| proscillaridin | 0.09±0.02 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| pyraclostrobin | 6.35±1.92 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| pyridate | 33.08±4.58 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| pyrinuron | 26.28±1.71 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| pyrvinium pamoate | 2.02±1.20 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| quercetin | 2.69±2.26 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| quercetin dihydrate | 6.20±2.32 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| rac benidipine hydrochloride | 14.96±3.18 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| rafoxanide | 3.27±1.76 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| raloxifene | 5.05±3.99 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| raloxifene hydrochloride | 6.69±1.65 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| resveratrol | 1.60±0.43 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| Rhein | 6.06±5.91 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| riboflavin | 7.02±1.78 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| rifampicin | 25.06±6.38 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| rifapentine | 1.46±0.26 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| rimonabant | 25.60±1.67 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| rolicyclidine | 22.29±2.32 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| Rotenone | 17.38±1.94 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| salicylanilide | 3.71±1.27 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| selenious acid | 15.97±22.77 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| siduron | 41.65±21.12 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| silwet l77 | 5.66±1.03 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| rapamycin | 20.08±2.07 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| sodium (4-fluoro-2-{[(1s)-1-phenylpropyl]carbamoyl}phenyl)(quinolin-8-ylsulfonyl)azanide | 4.42±6.97 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| sodium 2-phenylphenate tetrahydrate | 18.53±0.00 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| sodium bithionolate | 0.91±0.78 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| sodium warfarin | 38.57±12.82 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| sofalcone | 24.64±1.67 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| sorafenib | 0.96±0.09 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| sp600125 | 0.92±0.14 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| spiclomazine hydrochloride | 34.80±2.36 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| spiperone | 3.62±0.24 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| su-5416 | 12.53±1.78 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| sulfanitran | 26.60±8.77 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| surinabant | 33.08±16.61 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| talniflumate | 27.00±2.56 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| tamibarotene | 25.68±1.05 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| tamsulosin hydrochloride | 27.20±2.92 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| tau-fluvalinate | 37.16±15.12 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| tenidap | 12.53±1.19 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| tenonitrozole | 0.73±0.12 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| tenovin-1 | 3.27±2.74 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| tenoxicam | 8.36±1.07 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| tert-butyl 4-hydroxybenzoate | 25.29±7.32 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| tetra-aminopyrimidine sulfate | 18.70±11.39 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| tetrabromophenolphthalein ethyl ester | 23.80±6.89 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| tetrabutyltin | 5.66±1.03 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| tetradecylpyridinium bromide | 22.54±4.10 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| tetradifon | 15.34±7.43 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| tetraiodoethene | 5.45±1.27 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| tetra-n-octylammonium bromide | 0.13±0.09 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| tetraoctylphosphonium bromide | 0.18±0.12 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| tetrasul | 1.77±0.25 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| thidiazuron | 3.43±0.73 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| thiram | 1.94±25.92 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| tibrofan | 0.79±0.11 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| tioxidazole | 7.50±1.75 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| Tipranavir | 26.60±4.94 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| tolclofos-methyl | 30.64±5.80 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| Tolfenamic Acid | 11.88±0.00 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| toluidine blue | 3.48±1.60 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| tolvaptan | 17.44±8.01 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| transfluthrin | 25.01±4.09 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| tribenoside | 11.80±0.80 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| tribromosalan | 1.12±0.00 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| tributyltetradecylphosphonium chloride | 0.71±0.15 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| tributyltin benzoate | 0.15±0.23 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| tributyltin chloride | 0.11±0.02 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| tributyltin methacrylate | 0.07±0.01 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| tricirbine | 1.21±1.51 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| triclabendazole | 1.84±0.15 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| triclocarban | 0.14±0.05 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| triclosan | 1.50±0.88 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| triethoxy(2-methylpropyl)silane | 28.92±6.98 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| triethyltin bromide | 0.02±0.02 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| trifluralin | 46.68±9.14 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| trihexyltetradecylphosphonium bromide | 0.84±0.24 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| trihexyltetradecylphosphonium chloride | 0.77±0.35 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| trihexyltetradecylphosphonium dicyanamide | 0.39±0.19 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| trihexyltetradecylphosphonium hexafluorophosphate | 0.43±0.17 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| triphenyl phosphate | 1.38±1.48 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| triphenylethylene | 35.72±14.82 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| triphenyltin acetate | 0.12±0.04 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| triphenyltin fluoride | 0.47±0.31 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| triphenyltin hydroxide | 0.12±0.03 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| tris(2,3-dibromopropyl) phosphate | 45.81±8.72 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| Tyrothricin | 0.24±0.05 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| tyrphostin 23 | 17.70±6.46 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| vatalanib | 25.60±4.41 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| Verteporfin | 3.27±1.85 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| zafirlukast | 10.59±1.22 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| zearalenone | 4.67±1.77 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| (1,1,3,3-tetramethylbutyl)phenol | 3.98 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| (1'-ethyl-6,7-dihydro-5h-spiro[furo[2,3-f]indole-3,4'-piperidin]-5-yl)[2'-methyl-4'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-4-yl]methanone hydrochloride | 19.95 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| (2-ethyl-4-{[(4-{[4-(4-methoxyphenyl)piperazin-1-yl]methyl}-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl)methyl]sulfanyl}phenoxy)acetic acid | 31.62 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| (5-chloro-2-hydroxyphenyl)phenylmethanone | 39.81 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| (5s,8s)-5-(3,4-dichlorophenyl)-8-(methylamino)-5,6,7,8-tetrahydronaphthalene-2-sulfonamide | 10 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| (acryloyloxy)(tributyl)stannane | 0.4 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| (n-6)-methyladenine | 6.31 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| Diethylstilbestrol | 5.62 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1-(2,3,8,8-tetramethyl-1,2,3,4,5,6,7,8-octahydronaphthalen-2-yl)ethanone | 35.48 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1-(3,5,5,6,8,8-hexamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)ethanone | 28.18 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1,1,1-trichloropropanone | 3.16 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1,1,2-trimethyl-1h-benzo[e]indole | 10 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1,1':3',1''-terphenyl | 50.12 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1,2,5,6,9,10-hexabromocyclododecane | 6.31 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1,2-benzisothiazolin-3-one | 17.78 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1,2-phenylenediamine | 2.51 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1,2-phenylenediamine dihydrochloride | 1.78 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1,3,5-tris(4-tert-butyl-3-hydroxy-2,6-dimethylbenzyl)-1,3,5-triazinane-2,4,6-trione | 44.67 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1,3-didecyl-2-methylimidazolium chloride | 3.16 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1,3-diiminobenz(f)isoindoline | 35.48 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1,3-diphenyl-1,3-propanedione | 35.48 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1,4-benzenediamine | 2.18 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1,4-diaminoanthraquinone | 0.22 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1,4-dihydroxyanthracene-9,10-dione | 8.91 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1,4-naphthalenediamine | 2 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1,5-naphthalenediamine | 3.16 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1,8-dihydroxy-4,5-dinitroanthraquinone | 0.45 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| Mito-4509 | 22.39 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 17alpha-ethinylestradiol | 15.45 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1-amino-2-methylanthraquinone | 2.51 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1-benzyl-1-{[3-(4-chlorophenyl)-5-methyl-1-benzofuran-2-yl]methyl}-3-(2,4,6-trifluorophenyl)urea | 56.23 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1-decyl-3-methylimidazolium tetrafluoroborate | 7.08 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1-decyl-3-methylimidazolium trifluoromethanesulfonate | 7.08 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1-dodecyl-3-methylimidazolium hexafluorophosphate | 5.01 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1-fluoro-2,4-dinitrobenzene | 5.48 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1h,3h-naphtho(1,8-cd)pyran-1,3-dione | 7.94 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1h-benzo[de]isoquinoline-1,3(2h)-dione | 14.13 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1h-indole-2-carboxamide, n-[(3r)-1-(2-fluorophenyl)-3,4,6,7-tetrahydro-4-oxopyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl]- | 13.77 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1-hydroxypyrene | 7.08 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1-isocyanato-3-(trifluoromethyl)benzene | 6.31 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1-methyl-3-octylimidazolium hexafluorophosphate | 25.12 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1-methyl-3-octylimidazolium tetrafluoroborate | 19.95 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1-methyl-3-octylimidazolium trifluoromethanesulfonate | 15.85 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1-methylpyrene | 39.81 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1-naphthol | 31.62 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1-nitropyrene | 6.31 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| Edaravone | 28.18 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1-trans-delta-9-tetrahydrocannabinol | 15.45 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-(4-hydroxybenzyl)phenol | 35.48 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-(butan-2-yl)phenol | 25.12 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-(thiocyanomethylthio)benzothiazole | 56.23 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,2',4,4',5-pentabromodiphenyl ether | 4.47 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,2',6,6'-tetrachlorobisphenol a | 6.31 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,2'4,4'-tetrabromodiphenyl ether | 39.81 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane | 10 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,2-bis[(benzoyloxy)methyl]dibenzoate propanediol | 7.08 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,2'-dichlorobiphenyl | 63.1 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,2'-dihydroxy-4,4'-dimethoxybenzophenone | 12.59 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,2'-dihydroxy-4-methoxybenzophenone | 5.24 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,2'-methylenebis(4-methyl-6-tert-butylphenol) | 2 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,2'-methylenebis(ethyl-6-tert-butylphenol) | 2 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,3',4,4'-tetrahydroxybenzophenone | 8.91 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,3,4,5-tetrachlorophenol | 7.94 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,3,4-trichlorophenol | 7.94 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,3,5,6-tetrachlorophenol | 8.91 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,3,5-trichlorophenol | 6.31 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,4,5-trichlorophenol sodium salt | 10 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,4,6-trinitro-1,3-dimethyl-5-tert-butylbenzene | 7.94 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,4-bis(1-methyl-1-phenylethyl)phenol | 2.82 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,4-diaminoanisole sulfate | 7.94 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,4-dichloro-3,5-dimethylphenol | 8.91 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,4-diisopropylphenol | 35.48 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,4-di-tert-butylphenol | 3.98 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,5-bis(2-methylbutan-2-yl)benzene-1,4-diol | 3.55 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,5-di-tert-butylbenzene-1,4-diol | 7.94 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,6-bis-(1,1-dimethylethyl)-2,5-cyclohexadiene-1,4-dione | 39.81 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,6-di(butan-2-yl)phenol | 15.85 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,6-diaminopyridine | 35.48 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,6-di-tert-butyl-4-nitrophenol | 0.11 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,6-toluenediamine | 28.18 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 24r,25-dihydroxyvitamin d3 | 15.45 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-Acetylaminofluorene | 31.62 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-amino-4-(p-nitrophenyl)thiazole | 8.91 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-amino-4,6-dinitrophenol | 15.85 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-amino-4-chloro-5-nitrophenol | 25.12 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-amino-4-chlorobenzothiazole | 31.62 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-amino-5-nitrophenol | 35.48 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-amino-6-nitrobenzothiazole | 44.67 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-aminoanthracene | 3.55 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-aminoanthraquinone | 1.26 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-chloro-4-phenylphenol | 15.85 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-dodecylisoquinolinium tosylate | 4.35 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-ethylphenol | 15.85 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-hydrazino-4-(4-aminophenyl) thiazole | 0.4 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-hydrazino-4-(4-nitrophenyl)thiazole | 1.26 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-hydrazino-4-phenylthiazole | 10 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-hydroxyanthraquinone | 7.08 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-isovaleryl-1,3-indanedione | 56.23 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-methyl-1-nitroanthraquinone | 2.77 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-methylanthraquinone | 11.22 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-naphthalenesulfonic acid, 7-amino-4-hydroxy- | 39.81 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-naphthalenol | 35.48 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-nitro-1,4-phenylenediamine | 12.59 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-nitrofluorene | 50.12 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-phenylphenol | 28.18 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-propenal,3,3-diphenyl- | 56.23 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-tert-butyl-4-ethylphenol | 15.85 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-tert-butyl-4-methoxyphenol | 35.48 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-tert-butyl-5-methylphenol | 5.01 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 3-(5,5,6-trimethylbicyclo[2.2.1]hept-2-yl)cyclohexanol | 39.81 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 3,3',4,4'-tetraaminobiphenyl tetrahydrochloride | 2 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 3,3',5,5'-tetraiodothyroacetic acid | 39.04 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 3,3'-diaminobenzidine | 4.47 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 3,3'-dimethylbisphenol a | 11.22 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 3,3φ,5,5φ-tetrabromobisphenol a | 17.78 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 3,4,5-trichlorophenol | 5.01 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 3,4-dichlorophenol | 15.85 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 3,5-dichlorophenol | 11.22 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 3,5-dichlorosalicyl-3,4-dichloroanilide | 0.11 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 3-acetylphenanthrene | 56.23 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 3-amino-9-ethylcarbazole hydrochloride | 14.13 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 3-hydroxybenzophenone | 39.81 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 3-hydroxy-n-(3-nitrophenyl)naphthalene-2-carboxamide | 0.28 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 3-hydroxy-n-phenylaniline | 35.48 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 3-methylbenzene-1,2-diamine | 28.18 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 3-methylcholanthrene | 25.19 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 3-methyl-n-phenylaniline | 28.18 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-(1,1,3,3-tetramethylbutyl)phenol | 4.89 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-(2-methylbutan-2-yl)phenol | 35.48 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-(3-phenylpropyl)pyridine | 14.13 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-(benzyloxyl)phenol | 7.4 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-(butan-2-yl)phenol | 35.48 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4,4,4-trifluoro-1-phenyl-1,3-butanedione | 31.62 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4,4'-diaminoazobenzene | 5.62 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4,4'-diaminobenzanilide | 7.08 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4,4'-dichlorodiphenyl sulfone | 35.48 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4,4'-dinitrodiphenylurea | 0.97 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4,4'-methylenebis(2-chloroaniline) | 39.81 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4,4'-sulfonylbis[2-(prop-2-en-1-yl)phenol] | 15.85 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4,4'-thiobis(6-tert-butyl-m-cresol) | 3.16 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4,4'-thiodiphenol | 25.12 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4,6-dichloro-1,3-benzenediol | 15.85 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4,6-di-tert-butyl-m-cresol | 2.51 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-amino-2,6-dichlorophenol | 15.85 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-amino-2-nitrophenol | 14.13 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-amino-4φ-hydroxy-3-methyldiphenylamine | 14.13 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-benzylphenol | 31.62 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-chloro-1,2-diaminobenzene | 2 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-chloro-2-cyclopentylphenol | 6.31 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-chloro-3,5-dimethylphenol | 25.12 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-chlorophenyl isocyanate | 0.71 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-cumylphenol | 3.55 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4'-demethylepipodophyllotoxin | 2.18 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-dodecylphenol | 5.01 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-hexyl-4'-cyanobiphenyl | 31.62 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-hydroxybenzophenone | 28.18 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-methyl-2,6-dinitrophenol | 35.48 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-nitroanthranilic acid | 17.78 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-nitro-n-phenylaniline | 8.91 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-nitrosophenol | 15.85 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-octylphenol | 14.13 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-phenoxyphenol | 47.57 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-tert-butylcatechol | 31.62 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-tert-butylphenyl salicylate | 35.48 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 5,7-dichloro-8-hydroxy-2-methylquinoline | 1.38 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 5alpha-dihydrotestosterone | 17.34 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 5hpp-33 | 2.24 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| Busulfan | 2 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 5-nitroacenaphthene | 56.23 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 6-hydroxy-2-naphthyl disulfide | 28.18 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 9-aminoacridine, monohydrochloride, monohydrate | 21.82 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 9-anthracenemethanol | 19.95 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 9-nitroanthracene | 35.48 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 9-phenanthrol | 3.55 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| acenocoumarol | 9.32 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| aclarubicin hydrochloride | 2.45 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| acriflavine hydrochloride | 0.44 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| Albendazole | 19.45 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| aldrin | 39.81 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| alizarin | 13.77 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| allylestrenol | 31.62 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| aloe-emodin | 7.08 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| alpha-amylcinnamyl alcohol | 56.23 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| ambazone | 3.98 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| ami-193 | 7.74 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| aminoquinuride dihydrochloride | 27.48 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| amorolfine | 17.34 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| amsacrine hydrochloride | 56.23 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| amylmetacresol | 8.69 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| apigenin | 3.55 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| aroclor 1260 | 12.59 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| arotinolol hydrochloride | 27.48 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| axitinib | 1.09 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| barban | 25.12 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| bardoxolone methyl | 17.34 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| barium chloride | 39.81 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| basic blue 7 | 0.05 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| bazedoxifene | 15.45 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| beclazone | 21.82 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| benzbromarone | 13.77 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| benzidine | 15.85 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| benzidine dihydrochloride | 17.65 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| benziodarone | 4.35 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| benzoic acid, 2-[(4-chloro-3-methylphenyl)amino]- | 35.48 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| benzyldimethyltetradecylammonium chloride dihydrate | 13.77 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| benzyldodecyldimethylammonium bromide | 17.34 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| benzylhydrazine dihydrochloride | 19.95 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| berberine chloride | 3.46 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| betamethasone dipropionate | 19.45 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| bexarotene | 8.69 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| bis(tributyltin)oxide | 0.31 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| bisacodyl | 7.74 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| Bisphenol A | 15.85 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| bisphenol a glycidyl methacrylate | 15.85 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| bisphenol af | 5.01 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| bisphenol b | 10 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| bisphenol e | 25.12 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| bisphenol z | 19.95 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| bithionol | 0.97 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| bosutinib | 1.23 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| bromadiolone | 4.35 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| bromociclen | 15.45 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| bromocriptine | 21.82 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| bromocriptine mesylate | 13.5 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| bromofenoxim | 3.98 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| bromofos | 8.91 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| bromoxynil octanoate | 31.62 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| broquinaldol | 12.59 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| bryostatin 1 | 0.001 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| butylparaben | 35.48 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| c.i. 1040 | 7.74 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| c.i. basic orange 2 | 19.95 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| c.i. basic red 9 monohydrochloride | 0.56 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| c.i. basic violet 14 | 0.87 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| c.i. disperse blue 27 | 25.12 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| c.i. solvent yellow 14 | 15.85 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| calcifediol | 12.27 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| calcipotriene | 21.82 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| calcitriol | 15.45 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| candesartan cilexetil | 11.22 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| cannabinol | 1.09 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| cantharidin | 0.12 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| CCCP | 0.25 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| carminomycin | 21.82 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| chlorfenapyr | 0.04 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| chlorfenethol | 12.59 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| chlorfenson | 44.67 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| chlorfluazuron | 12.59 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| chlorophacinone | 3.55 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| chloropropylate | 44.67 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| chloroxine | 9.75 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| chromomycin | 35.48 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| chrysarobin | 30.83 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| chrysin | 7.08 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| ciclesonide | 15.45 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| Ciglitazone | 14.13 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| cilnidipine | 12.27 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| cinalukast | 17.34 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| clobetasol | 17.34 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| cloflucarban | 0.44 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| clofoctol | 4.35 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| clonixin | 22.39 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| cloxyquin | 15.45 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| coumatetralyl | 35.48 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| cresyl diphenyl phosphate | 3.55 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| curcumin | 2.51 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| d&c yellow 11 | 0.44 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| danthron | 15.45 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| dantrolene sodium | 3.46 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| darbufelone mesylate | 5.62 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| deltamethrin | 50.12 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| deslanoside | 0.44 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| desogestrel | 27.48 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| devazepide | 10.94 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| dexamethasone valerate | 17.34 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| diacerein | 17.34 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| dianiline | 21.82 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| dibutyltin dilaurate | 27.48 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| dichlofluanid | 25.12 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| dichlorodiphenylsilane | 22.39 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| diclazuril | 8.69 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| dicofol | 8.91 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| N,N'-dicyclohexylcarbodiimide | 0.02 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| dienestrol | 8.3 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| Diethylstilbestrol | 6.31 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| diethylstilbestrol dipropionate | 7.08 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| digitoxin | 0.06 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| digoxin | 0.13 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| dinex | 0.71 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| diniconazole | 8.91 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| dinobuton | 7.94 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| dinocap | 0.63 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| dinoterb | 2.24 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| diphenan | 19.95 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| diphenoxylate hydrochloride | 17.34 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| diphenylcyclopropenone | 27.48 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| diphenylurea | 2.51 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| disperse red 82 | 6.31 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| dithiazanine chloride | 0.15 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| dithiazanine iodide | 0.03 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| dodecyl gallate | 7.94 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| dodecylparaben | 7.94 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| dodecylphenol | 3.16 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| doramapimod;bibr-796? | 21.82 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| doramectin | 17.34 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| ebselen | 19.45 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| emodin | 2.51 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| endosulfan sulfate | 17.78 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| endrin | 21.82 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| enterolactone | 10.72 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| eprinomectin (b1a, b1b mixture) | 8.69 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| equilin | 31.62 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| estradiol acetate | 17.34 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| ethacridine lactate hydrate | 5.48 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| ethalfluralin | 44.67 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| ethanol, 2,2'-((1-methylethylidene)bis((2,6-dibromo-4,1-phenylene)oxy))bis- | 10.97 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| ethoxazene | 2.82 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| ethynodiol diacetate | 21.82 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| etocarlide | 25.12 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| everolimus | 27.48 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| ezetimibe | 8.69 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| famoxadone | 4.47 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| fenamidone | 19.95 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| fenarimol | 35.48 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| fenchlorphos | 6.15 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| fendiline hydrochloride | 9.75 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| fenhexamid | 17.78 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| fenretinide | 4.89 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| fentiazac | 19.45 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| fenticlor | 5.48 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| fenvalerate | 35.48 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| flopropione | 17.34 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| fluazuron | 12.27 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| flubendiamide | 25.33 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| flucythrinate | 31.62 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| Flufenamic Acid | 17.34 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| flunixin meglumine | 7.4 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| fluorodifen | 28.18 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| fluorosalan | 0.19 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| fluoxastrobin | 11.22 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| folpet | 14.13 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| forchlorfenuron | 1 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| formononetin | 17.78 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| fulvestrant | 5.48 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| geliomycin | 0.19 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| genistein | 10 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| gentian violet | 0.35 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| gramicidin | 0.04 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| halobetasol propionate | 13.77 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| heptachlor | 31.62 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| Hexachlorophene | 0.63 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| indole-3-pyruvic acid | 11.22 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| indoxacarb | 15.27 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| iodophthalein | 4.35 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| iodophthalein sodium | 6.9 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| isobutylparaben | 14.13 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| isodrin | 35.48 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| isoxaben | 14.13 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| isoxicam | 2.75 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| israpafant | 27.48 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| kaempferol | 6.76 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| kepone | 2.82 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| Ketoconazole | 5.48 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| lambda-cyhalothrin | 15.85 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| lanatoside a | 0.14 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| lanatoside b | 0.69 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| lanatoside c | 0.31 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| lapachol | 31.62 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| lasalocid sodium | 1.38 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| lercanidipine hydrochloride | 8.69 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| lestaurtinib | 5.62 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| lornoxicam | 6.15 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| lufenuron | 14.13 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| lynestrenol | 7.4 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| lysergide | 17.34 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| malachite green oxalate | 27.48 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| malotilate | 39.81 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| manidipine | 27.48 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| Mebendazole | 2.34 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| mepartricin | 6.9 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| mepronil | 39.81 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| mesotrione | 39.81 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| metanixin | 21.82 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| methfuroxam | 17.78 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| methisazone | 12.59 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| Methoxychlor | 28.18 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| methyl 2,4-dihydroxy-3,6-dimethylbenzoate | 25.12 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| methyl triclosan | 39.81 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| methyl violet | 0.44 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| methyldigoxin | 0.24 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| Methylene Blue | 2.75 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| methylene blue trihydrate | 4.82 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| methyltrioctylammonium trifluoromethanesulfonate | 2.24 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| metochalcone | 39.81 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| mgk-264 | 28.18 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| miripirium chloride | 8.69 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| mk-2206 | 17.34 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| mometasone furoate | 8.3 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| n,n-diethylbenzene-1,4-diamine | 7.94 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| n,n-dimethyl-p-phenylenediamine | 7.08 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| n-benzyl-6-ethoxy-4-oxo-1,4-dihydro-1,5-naphthyridine-3-carboxamide | 15.85 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| nelfinavir mesylate | 30.83 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| Niclosamide | 0.1 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| niflumic acid | 15.45 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| nifuroxazide | 2.34 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| Nimesulide | 4.16 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| ninhydrin | 56.23 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| Nitazoxanide | 1.26 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| Nitrofurantoin | 8.69 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| nitrovin | 5.48 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| nitroxoline | 19.95 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| n-methyl-n,n-dioctyloctan-1-aminium chloride | 10 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| nocodazole | 2.18 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| nonylparaben | 7.94 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| norelgestromin | 19.45 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| noristerat | 21.82 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| n-phenyl-1,4-benzenediamine hydrochloride | 28.18 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| o,p'-ddd | 19.45 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| o,p'-ddt | 25.12 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| osalmid | 6.31 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| ouabain | 0.22 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| oxyphenisatin acetate | 17.34 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| p,p'-ddd | 39.81 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| p,p'-dde | 44.67 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| p,p'-ddt | 30.83 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| palmatine chloride hydrate | 12.59 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| p-benzoquinone dioxime | 25.12 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| penfluridol | 27.48 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,2',4,4',5-pentabromodiphenyl ether | 8.91 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| pentabromophenol | 7.94 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| Pentachlorophenol | 8.9 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| pentylparaben | 14.13 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| perfluorooctanesulfonamide | 2.51 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| phenmedipham | 7.08 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| phenol, 4,4'-butylidenebis[2-(1,1-dimethylethyl)-5-methyl- | 7.08 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| phenol, 4-methyl-, reaction products with dicyclopentadiene and isobutylene | 8.69 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| phenolphthalein | 25.12 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| phenoxybenzamine hydrochloride | 35.48 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| phenyl isothiocyanate | 35.48 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| phloretin | 11.22 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| picoxystrobin | 1 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| picropodophyllin | 0.05 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| pinacyanol | 0.02 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| pirarubicin | 0.69 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| Piroxicam | 5.88 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| polyethylene glycol (9z)-9-octadecenyl ether | 7.94 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| polyoxyethylene(10)nonylphenyl ether | 4.89 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| p-phenylazophenol | 10 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| prodiamine | 8.91 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| profenofos | 6.15 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| proflavin hemisulfate | 3.46 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| proflavin hydrochloride | 3.55 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| profluralin | 39.81 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| propan-2-yl (2r,4s)-4-{acetyl[3,5-bis(trifluoromethyl)benzyl]amino}-2-ethyl-6-(trifluoromethyl)-3,4-dihydroquinoline-1(2h)-carboxylate | 4.47 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| propyl gallate | 35.48 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| propylparaben | 35.48 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| proscillaridin | 0.07 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| pyraclostrobin | 1.26 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| pyridate | 35.48 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| pyrinuron | 28.18 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| pyrvinium pamoate | 0.17 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| quercetin | 3.16 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| quercetin dihydrate | 2.95 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| rac benidipine hydrochloride | 30.83 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| rafoxanide | 1.23 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| raloxifene | 17.78 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| raloxifene hydrochloride | 7.94 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| resveratrol | 3.71 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| Rhein | 8.91 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| riboflavin | 11.22 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| rifampicin | 15.45 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| rifapentine | 3.88 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| rimonabant | 17.34 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| Rotenone | 0.01 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| salicylanilide | 3.98 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| siduron | 35.48 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| silwet l77 | 8.91 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| sodium (4-fluoro-2-{[(1s)-1-phenylpropyl]carbamoyl}phenyl)(quinolin-8-ylsulfonyl)azanide | 11.22 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| sodium 2-phenylphenate tetrahydrate | 31.62 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| sodium bithionolate | 0.89 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| sodium warfarin | 35.48 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| sofalcone | 17.34 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| sorafenib | 1.23 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| sp600125 | 1.55 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| spiperone | 3.46 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| su-5416 | 13.77 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| sulfanitran | 17.34 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| surinabant | 19.95 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| tamibarotene | 13.77 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| tamsulosin hydrochloride | 30.83 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| tau-fluvalinate | 31.62 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| tenidap | 15.85 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| tenonitrozole | 0.56 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| tenovin-1 | 3.88 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| tenoxicam | 6.6 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| tert-butyl 4-hydroxybenzoate | 35.48 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| tetra-aminopyrimidine sulfate | 25.12 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| tetrabromophenolphthalein ethyl ester | 26.55 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| tetrabutyltin | 11.22 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| tetradecylpyridinium bromide | 17.78 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| tetradifon | 17.78 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| tetraiodoethene | 6.31 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| tetra-n-octylammonium bromide | 0.13 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| tetraoctylphosphonium bromide | 0.32 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| tetrasul | 2.51 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| thidiazuron | 6.31 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| thiram | 24.49 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| tibrofan | 0.87 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| tioxidazole | 15.45 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| Tipranavir | 17.34 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| tolclofos-methyl | 39.81 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| Tolfenamic Acid | 17.34 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| toluidine blue | 4.89 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| tolvaptan | 19.45 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| transfluthrin | 19.45 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| tribenoside | 11.73 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| tribromosalan | 0.97 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| tributyltetradecylphosphonium chloride | 1.12 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| tributyltin benzoate | 0.5 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| tributyltin chloride | 0.89 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| tributyltin methacrylate | 0.45 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| tricirbine | 0.49 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| triclabendazole | 5.48 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| triclocarban | 0.17 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| triclosan | 6.15 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| triethoxy(2-methylpropyl)silane | 35.48 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| triethyltin bromide | 0.2 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| trifluralin | 39.81 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| trihexyltetradecylphosphonium bromide | 0.45 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| trihexyltetradecylphosphonium chloride | 0.89 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| trihexyltetradecylphosphonium dicyanamide | 0.89 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| trihexyltetradecylphosphonium hexafluorophosphate | 1.12 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| triphenyl phosphate | 1.26 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| triphenylethylene | 31.62 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| triphenyltin acetate | 1.12 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| triphenyltin fluoride | 1.78 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| triphenyltin hydroxide | 1.12 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| tris(2,3-dibromopropyl) phosphate | 50.12 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| Tyrothricin | 0.24 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| tyrphostin 23 | 17.34 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| vatalanib | 30.83 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| Verteporfin | 8.69 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| zafirlukast | 13.77 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| zearalenone | 5.84 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| (1,1,3,3-tetramethylbutyl)phenol | 42.24±3.43 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| (1'-ethyl-6,7-dihydro-5h-spiro[furo[2,3-f]indole-3,4'-piperidin]-5-yl)[2'-methyl-4'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-4-yl]methanone hydrochloride | 40.87±16.01 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| (2-ethyl-4-{[(4-{[4-(4-methoxyphenyl)piperazin-1-yl]methyl}-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl)methyl]sulfanyl}phenoxy)acetic acid | 23.10±15.57 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| (2-nitro-1-propenyl)benzene | 25.94±8.35 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| (5-chloro-2-hydroxyphenyl)phenylmethanone | 25.43±21.27 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| (5s,8s)-5-(3,4-dichlorophenyl)-8-(methylamino)-5,6,7,8-tetrahydronaphthalene-2-sulfonamide | 35.72±5.79 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| (acryloyloxy)(tributyl)stannane | 8.49±2.50 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| Diethylstilbestrol | 42.80±10.35 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 1,1,1-trichloropropanone | 23.74±29.59 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 1,1,2-trimethyl-1h-benzo[e]indole | 34.91±8.48 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 1,1':3',1''-terphenyl | 29.58±27.73 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 1,2,5,6,9,10-hexabromocyclododecane | 32.03±16.51 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 1,2-phenylenediamine | 17.85±6.50 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 1,2-phenylenediamine dihydrochloride | 14.22±2.30 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 1,3,5-tris(4-tert-butyl-3-hydroxy-2,6-dimethylbenzyl)-1,3,5-triazinane-2,4,6-trione | 26.79±25.28 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 1,3-didecyl-2-methylimidazolium chloride | 26.25±3.35 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 1,3-diiminobenz(f)isoindoline | 26.72±23.58 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 1,3-diphenyl-1,3-propanedione | 39.83±14.21 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 1,4-diaminoanthraquinone | 1.24±0.76 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 1,4-dihydroxyanthracene-9,10-dione | 4.81±8.07 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 1,4-naphthalenediamine | 22.71±8.75 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 1,8-dihydroxy-4,5-dinitroanthraquinone | 5.69±2.62 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 10-chloro-9-anthraldehyde | 24.28±28.84 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| Mito-4509 | 35.48±0.00 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 17alpha-ethinylestradiol | 18.39±1.50 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 1-amino-2,4-dibromoanthraquinone | 27.37±4.44 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 1-amino-2-methylanthraquinone | 5.28±3.30 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 1-decyl-3-methylimidazolium tetrafluoroborate | 16.76±7.73 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 1-decyl-3-methylimidazolium trifluoromethanesulfonate | 12.13±3.97 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 1-dodecyl-3-methylimidazolium hexafluorophosphate | 8.81±2.46 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 1-fluoro-2,4-dinitrobenzene | 8.30±5.67 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 1h-benzo[de]isoquinoline-1,3(2h)-dione | 5.56±8.92 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 1h-indole-2-carboxamide, n-[(3r)-1-(2-fluorophenyl)-3,4,6,7-tetrahydro-4-oxopyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl]- | 17.34±0.00 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 1-hydroxypyrene | 33.55±2.73 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 1-isocyanato-3-(trifluoromethyl)benzene | 11.52±3.69 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 1-methyl-3-octylimidazolium hexafluorophosphate | 39.81±0.00 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 1-methyl-3-octylimidazolium tetrafluoroborate | 43.42±7.40 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 1-methyl-3-octylimidazolium trifluoromethanesulfonate | 31.62±0.00 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 1-methylpyrene | 32.18±7.36 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 1-nitronaphthalene | 45.86±14.67 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 1-nitropyrene | 16.88±4.77 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| Edaravone | 25.79±10.10 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-(thiocyanomethylthio)benzothiazole | 30.47±26.36 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,2',4,4',5-pentabromodiphenyl ether | 9.11±4.93 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,2',6,6'-tetrachlorobisphenol a | 29.74±11.13 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,2'4,4'-tetrabromodiphenyl ether | 25.56±34.73 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane | 33.22±24.22 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,2'-dihydroxy-4,4'-dimethoxybenzophenone | 29.81±13.75 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,2'-dihydroxy-4-methoxybenzophenone | 11.08±5.21 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,2'-methylenebis(4-methyl-6-tert-butylphenol) | 3.71±0.47 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,2'-methylenebis(ethyl-6-tert-butylphenol) | 5.01±4.35 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,3',4,4'-tetrahydroxybenzophenone | 40.36±8.45 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,3,4,5-tetrachlorophenol | 11.55±5.42 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,3,4-trichlorophenol | 41.79±14.43 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,3,5,6-tetrachlorophenol | 9.20±2.96 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,3,5-trichlorophenol | 27.65±10.40 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,4,5-trichlorophenol sodium salt | 27.31±25.25 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,4-bis(1-methyl-1-phenylethyl)phenol | 43.93±17.40 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,4-diaminoanisole sulfate | 19.62±19.34 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,4-di-tert-butylphenol | 24.04±16.59 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,5-bis(2-methylbutan-2-yl)benzene-1,4-diol | 34.49±5.88 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,5-di-tert-butylbenzene-1,4-diol | 39.15±15.51 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,6-diaminopyridine | 20.88±15.73 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,6-di-tert-butyl-4-nitrophenol | 0.29±0.30 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,6-toluenediamine | 32.18±7.36 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 24r,25-dihydroxyvitamin d3 | 17.34±0.00 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-amino-4-(p-nitrophenyl)thiazole | 20.55±21.11 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-amino-4,6-dinitrophenol | 28.80±15.58 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-amino-4-chloro-5-nitrophenol | 31.27±8.72 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-amino-4-chlorobenzothiazole | 24.04±16.19 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-amino-5-nitrophenol | 52.13±17.74 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-amino-6-nitrobenzothiazole | 22.74±20.35 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-aminoanthracene | 0.18±0.20 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-aminoanthraquinone | 3.57±2.61 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-chloro-4-phenylphenol | 31.76±3.65 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-dodecylisoquinolinium tosylate | 4.94±2.78 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-hydrazino-4-(4-aminophenyl) thiazole | 3.55±3.86 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-hydrazino-4-(4-nitrophenyl)thiazole | 7.90±5.75 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-hydrazino-4-phenylthiazole | 21.46±17.61 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-hydroxy-4-methoxybenzophenone | 50.14±18.89 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-hydroxyanthraquinone | 17.28±6.83 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-isovaleryl-1,3-indanedione | 22.25±11.09 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-methyl-1-nitroanthraquinone | 16.95±14.73 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-methylanthraquinone | 5.97±0.49 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-naphthalenol | 42.21±19.83 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-nitro-1,4-phenylenediamine | 18.06±14.95 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-nitrofluorene | 38.15±9.22 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-phenylphenol | 53.18±4.32 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-propenal,3,3-diphenyl- | 17.12±23.88 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-tert-butyl-4-methoxyphenol | 36.50±19.25 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-tert-butyl-5-methylphenol | 40.07±6.50 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 3,3',4,4'-tetraaminobiphenyl tetrahydrochloride | 9.46±4.43 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 3,3',5,5'-tetraiodothyroacetic acid | 26.13±2.13 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 3,3'-diaminobenzidine | 30.66±28.30 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 3,3'-dimethylbisphenol a | 34.35±4.73 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 3,3φ,5,5φ-tetrabromobisphenol a | 36.91±12.56 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 3,4,5-trichlorophenol | 33.82±17.20 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 3,4-dichlorophenol | 53.88±13.03 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 3,5-dichlorophenol | 46.90±8.44 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 3,5-dichlorosalicyl-3,4-dichloroanilide | 0.38±0.03 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 3-acetylphenanthrene | 42.21±19.83 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 3-amino-9-ethylcarbazole hydrochloride | 56.23±0.00 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 3-hydroxy-n-(3-nitrophenyl)naphthalene-2-carboxamide | 1.60±0.26 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 3-methylbenzene-1,2-diamine | 36.64±11.80 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 3-methyl-n-phenylaniline | 35.48±0.00 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-(3-phenylpropyl)pyridine | 12.95±6.83 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-(benzyloxyl)phenol | 9.04±8.10 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 4,4'-diaminoazobenzene | 26.63±12.51 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 4,4'-diaminobenzanilide | 33.55±2.73 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 4,4'-dichlorodiphenyl sulfone | 29.90±2.43 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 4,4'-dinitrodiphenylurea | 0.70±0.46 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 4,4'-methylenebis(2-chloroaniline) | 56.23±0.00 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 4,4'-sulfonylbis[2-(prop-2-en-1-yl)phenol] | 24.48±19.89 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 4,4'-thiobis(6-tert-butyl-m-cresol) | 24.82±11.78 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 4,4'-thiodiphenol | 24.70±9.79 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 4,6-dichloro-1,3-benzenediol | 35.72±5.79 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 4,6-di-tert-butyl-m-cresol | 45.86±14.67 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-amino-2,6-dichlorophenol | 29.55±27.78 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-amino-2-nitrophenol | 33.55±2.73 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-chloro-1,2-diaminobenzene | 11.03±4.37 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-chloro-2-cyclopentylphenol | 33.65±29.67 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-chlorophenyl isocyanate | 1.56±0.39 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-cumylphenol | 48.02±11.61 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-dodecylphenol | 25.12±21.80 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-hexyl-4'-cyanobiphenyl | 17.52±15.62 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-hydroxybenzophenone | 17.79±28.01 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-methyl-2,6-dinitrophenol | 15.14±6.79 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-nitro-n-phenylaniline | 23.93±7.05 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-octyloxybenzoic acid | 48.02±11.61 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-octylphenol | 53.18±4.32 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 5hpp-33 | 29.09±12.18 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| Busulfan | 6.15±3.62 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 5-nitroacenaphthene | 24.04±16.19 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 6-hydroxy-2-naphthyl disulfide | 39.81±0.00 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 6-nitroquinoline | 44.84±16.33 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 9,10-dihydrobenzo[a]pyren-7(8h)-one | 16.82±7.33 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 9-aminoacridine, monohydrochloride, monohydrate | 8.51±5.35 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 9-anthracenemethanol | 21.66±15.72 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 9-cyanoanthracene | 17.99±5.46 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 9-nitroanthracene | 33.05±4.21 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 9-phenanthrol | 47.28±10.66 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| acenocoumarol | 4.59±1.82 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| acetaldehyde | 6.65±4.48 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| aclarubicin hydrochloride | 6.89±9.73 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| acriflavine hydrochloride | 3.55±1.14 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| Albendazole | 15.46±21.73 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| alizarin | 11.87±7.79 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| aloe-emodin | 8.43±5.96 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| alpha-1,2,3,4,5,6-hexachlorocyclohexane | 39.81±0.00 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| alpha-amylcinnamyl alcohol | 4.83±4.07 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| ambazone | 1.98±2.22 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| ami-193 | 25.96±12.20 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| amsacrine hydrochloride | 37.65±3.06 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| anthrone | 42.40±11.98 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| apigenin | 28.93±9.26 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| barban | 35.97±7.53 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| bardoxolone methyl | 17.41±2.00 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| basic blue 7 | 1.53±1.42 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| beclazone | 16.28±20.57 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| benzbromarone | 4.91±1.79 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| benzidine | 2.51±3.54 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| benziodarone | 1.76±0.68 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| benzoic acid, 2-[(4-chloro-3-methylphenyl)amino]- | 22.71±16.22 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| benzyldodecyldimethylammonium bromide | 18.39±1.50 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| berberine chloride | 6.03±3.78 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| bexarotene | 9.08±1.16 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| bisacodyl | 18.39±13.00 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| Bisphenol A | 37.65±3.06 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| bisphenol a glycidyl methacrylate | 38.15±9.22 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| bisphenol af | 37.26±6.70 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| bisphenol b | 21.75±8.60 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| bisphenol e | 36.50±19.25 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| bisphenol z | 14.71±15.12 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| bithionol | 2.47±1.39 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| bosutinib | 16.59±11.17 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| bromadiolone | 3.40±0.83 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| bromocriptine | 13.20±10.83 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| bromocriptine mesylate | 12.57±1.60 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| bromofenoxim | 2.18±0.86 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| bromofos | 22.65±10.42 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| bromoxynil octanoate | 28.63±22.68 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| broquinaldol | 38.61±34.63 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| bryostatin 1 | 0.79±1.07 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| c.i. 1040 | 19.72±4.13 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| c.i. basic orange 2 | 24.91±21.08 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| c.i. basic red 9 monohydrochloride | 4.11±4.24 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| c.i. basic violet 14 | 6.84±4.71 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| c.i. disperse blue 27 | 32.46±10.39 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| c.i. solvent yellow 14 | 17.04±10.60 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| calcifediol | 14.21±9.57 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| calcipotriene | 17.34±0.00 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| calcitriol | 22.41±7.17 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| cannabinol | 21.82±0.00 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| cantharidin | 0.45±0.30 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| chlorfenapyr | 0.07±0.01 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| chlorfenethol | 18.94±5.35 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| chlorfenson | 23.70±17.18 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| chlorfluazuron | 29.33±1.99 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| chlorophacinone | 4.65±4.78 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| chloropropylate | 43.84±10.95 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| chrysarobin | 19.29±8.27 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| chrysin | 30.60±28.39 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| Ciglitazone | 9.92±4.25 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| cilnidipine | 14.79±8.07 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| cinalukast | 13.54±5.36 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| clobetasol | 19.76±15.65 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| clobetasol propionate | 24.08±9.54 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| cloflucarban | 0.58±0.05 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| clofoctol | 15.67±6.04 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| clonixin | 18.31±5.10 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| coumatetralyl | 13.76±8.10 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| cresyl diphenyl phosphate | 22.99±9.00 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| curcumin | 11.60±9.87 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| cybutryne | 14.30±16.00 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| cyhalothrin | 33.80±9.96 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| danthron | 5.97±5.35 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| dantrolene sodium | 15.52±1.78 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| darbufelone mesylate | 7.15±5.41 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| deltamethrin | 39.83±14.21 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| devazepide | 15.63±7.19 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| dexamethasone valerate | 23.46±5.67 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| diacerein | 14.17±11.27 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| dibutyltin dilaurate | 22.41±7.17 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| dichlofluanid | 22.96±29.49 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| diclazuril | 5.70±1.94 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| dicofol | 24.64±9.27 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| Diethylstilbestrol | 25.19±21.68 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| diethylstilbestrol dipropionate | 49.29±19.53 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| dinex | 1.40±0.60 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| diniconazole | 36.04±28.56 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| dinobuton | 5.74±4.21 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| dinocap | 4.10±2.16 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| dinoterb | 0.76±0.45 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| diphenan | 84.22±39.58 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| diphenoxylate hydrochloride | 19.45±0.00 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| diphenylurea | 8.46±2.39 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| disperse red 82 | 11.68±8.76 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| dithiazanine chloride | 2.45±0.00 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| dithiazanine iodide | 0.98±0.16 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| docetaxel | 12.07±4.78 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| dodecyl gallate | 48.72±8.30 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| dodecylphenol | 41.11±13.24 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| doramapimod;bibr-796? | 24.08±9.54 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| ebselen | 21.42±5.35 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| emodin | 6.28±4.57 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| endosulfan sulfate | 25.80±10.10 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| eprinomectin (b1a, b1b mixture) | 8.28±2.44 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| equilin | 39.15±15.51 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| ethacridine lactate hydrate | 10.25±5.58 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| ethanol, 2,2'-((1-methylethylidene)bis((2,6-dibromo-4,1-phenylene)oxy))bis- | 32.82±2.67 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| ethoxazene | 4.96±3.42 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| etocarlide | 27.65±10.40 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| everolimus | 13.01±7.49 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| exalamide | 29.15±2.37 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| ezetimibe | 16.64±20.07 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| famoxadone | 8.38±6.71 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| fenamidone | 42.80±10.35 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| fenarimol | 33.55±2.73 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| fenchlorphos | 20.64±1.68 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| fenhexamid | 36.72±21.22 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| fentiazac | 9.49±7.98 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| fenticlor | 13.88±8.84 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| fluazuron | 9.83±13.60 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| flubendiamide | 12.80±8.15 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| flucythrinate | 43.93±17.40 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| Flufenamic Acid | 14.45±4.99 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| flunixin meglumine | 5.77±4.59 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| fluorodifen | 24.07±14.98 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| fluorosalan | 0.42±0.48 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| fluoxastrobin | 37.94±19.29 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| folpet | 33.72±20.15 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| forchlorfenuron | 2.19±1.97 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| formononetin | 13.20±16.25 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| fulvestrant | 8.84±12.01 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| geliomycin | 0.55±0.31 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| genistein | 33.67±19.54 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| gentian violet | 1.34±0.11 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| glycyrrhetinic acid | 15.55±2.52 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| gramicidin | 0.20±0.21 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| halobetasol propionate | 25.21±7.02 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| Hexachlorophene | 1.00±0.74 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| hydroxystilbamidine bis(methanesulfonate) | 13.60±8.28 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| idarubicin hydrochloride | 27.02±10.70 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| indole-3-pyruvic acid | 21.29±17.89 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| indoxacarb | 34.42±5.58 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| iodophthalein | 7.32±0.60 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| iodophthalein sodium | 8.73±1.00 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| isoxicam | 4.92±0.80 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| israpafant | 23.46±5.67 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| kaempferol | 24.06±8.76 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| kepone | 10.15±9.25 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| lambda-cyhalothrin | 28.18±0.00 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| lasalocid sodium | 1.30±0.29 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| lercanidipine hydrochloride | 27.48±0.00 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| lestaurtinib | 12.76±2.67 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| lopinavir | 15.42±21.79 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| lornoxicam | 3.30±2.52 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| lufenuron | 44.96±7.29 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| malachite green oxalate | 8.67±12.26 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| malotilate | 23.92±29.35 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| manidipine | 20.91±5.06 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| mepartricin | 27.66±4.48 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| mepronil | 56.23±0.00 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| metanixin | 21.03±1.37 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| methisazone | 21.51±9.04 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| Methoxychlor | 27.72±10.98 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| methyl 2,4-dihydroxy-3,6-dimethylbenzoate | 30.57±28.43 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| methyl triclosan | 45.86±14.67 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| methyl violet | 1.73±0.00 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| methylene blue trihydrate | 7.29±7.49 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| methyltrioctylammonium trifluoromethanesulfonate | 11.36±2.12 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| metochalcone | 25.48±18.19 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| mgk-264 | 17.77±25.05 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| miripirium chloride | 19.54±2.25 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| mometasone furoate | 13.96±1.14 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| montelukast sodium | 24.08±9.54 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| n,n-diethylbenzene-1,4-diamine | 31.62±0.00 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| n,n-dimethyl-p-phenylenediamine | 21.66±15.72 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| n,nφ-diethylcarbanilide | 13.11±16.35 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| n-benzyl-6-ethoxy-4-oxo-1,4-dihydro-1,5-naphthyridine-3-carboxamide | 24.04±16.59 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| n-cyclohexyl-4-methyl benzenesulfonamide | 38.09±25.65 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| nelfinavir mesylate | 8.68±12.24 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| Niclosamide | 0.44±0.27 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| niflumic acid | 6.71±1.14 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| nifuroxazide | 6.71±1.54 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| Nimesulide | 2.74±0.35 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| Nitazoxanide | 6.94±4.36 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| Nitrofurantoin | 7.26±6.35 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| nitrovin | 16.39±1.33 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| nitroxoline | 72.33±39.13 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| n-methyl-n,n-dioctyloctan-1-aminium chloride | 19.58±4.89 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| n-nitroso-n-methyl-4-nitroaniline | 20.04±16.60 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| norelgestromin | 13.37±12.30 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| o,p'-ddd | 24.18±14.72 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| osalmid | 30.03±21.28 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| oxyphenisatin acetate | 20.64±1.68 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| p,p'-ddd | 42.21±19.83 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| palmatine chloride hydrate | 1.37±0.70 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| penfluridol | 23.24±6.57 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,2',4,4',5-pentabromodiphenyl ether | 32.91±2.23 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| pentabromophenol | 4.98±2.48 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| Pentachlorophenol | 4.17±0.75 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| perfluorooctanesulfonamide | 1.47±0.10 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| phenazopyridine hydrochloride | 23.75±1.93 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| phenmedipham | 19.38±9.11 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| phenol, 4,4'-butylidenebis[2-(1,1-dimethylethyl)-5-methyl- | 21.10±18.22 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| phenol, 4-methyl-, reaction products with dicyclopentadiene and isobutylene | 0.11±0.07 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| phenolphthalein | 39.48±16.93 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| phloretin | 10.60±4.98 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| picoxystrobin | 14.60±4.70 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| pinacyanol | 0.04±0.01 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| pioglitazone hydrochloride | 8.90±9.20 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| pirarubicin | 0.03±0.00 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| Piroxicam | 4.79±1.53 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| polyethylene glycol (9z)-9-octadecenyl ether | 40.87±13.08 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| prodiamine | 25.42±11.69 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| profenofos | 13.19±3.19 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| proflavin hemisulfate | 11.60±5.45 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| proflavin hydrochloride | 15.91±5.23 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| profluralin | 25.06±35.43 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| pyraclostrobin | 9.04±1.89 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| pyridate | 50.45±8.18 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| pyrinuron | 25.79±10.10 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| pyrvinium pamoate | 1.03±0.26 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| quercetin | 15.14±6.79 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| quercetin dihydrate | 5.83±4.93 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| rafoxanide | 1.86±0.83 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| raloxifene | 22.40±24.05 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| raloxifene hydrochloride | 20.94±7.23 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| Rhein | 11.58±4.85 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| riboflavin | 31.27±8.72 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| rifampicin | 6.15±2.20 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| rifapentine | 0.62±0.55 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| rimonabant | 17.45±2.83 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| Rotenone | 0.20±0.30 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| salicylanilide | 29.09±12.18 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| selenious acid | 44.11±26.85 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| siduron | 43.93±17.40 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| silwet l77 | 14.31±2.67 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| rapamycin | 20.64±1.68 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| sodium (4-fluoro-2-{[(1s)-1-phenylpropyl]carbamoyl}phenyl)(quinolin-8-ylsulfonyl)azanide | 35.85±20.20 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| sodium warfarin | 35.48±0.00 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| sofalcone | 19.54±2.25 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| sorafenib | 2.25±0.63 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| sp600125 | 21.13±2.91 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| spiperone | 2.92±0.24 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| su-5416 | 11.01±1.78 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| sulfanitran | 19.54±2.25 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| surinabant | 34.31±22.53 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| talniflumate | 15.95±6.68 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| tamibarotene | 9.06±6.66 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| tamsulosin hydrochloride | 25.14±8.04 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| tenidap | 21.05±7.88 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| tenonitrozole | 0.68±0.45 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| tenovin-1 | 18.39±1.50 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| tenoxicam | 4.23±3.79 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| tert-butyl 4-hydroxybenzoate | 50.76±9.48 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| tetra-aminopyrimidine sulfate | 42.14±30.55 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| tetrabromophenolphthalein ethyl ester | 13.85±0.94 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| tetrabutylphosphonium chloride | 15.30±5.00 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| tetradecylpyridinium bromide | 33.55±2.73 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| tetradifon | 12.05±6.57 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| tetraiodoethene | 22.56±14.37 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| tetraoctylphosphonium bromide | 6.82±2.23 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| thidiazuron | 4.56±2.78 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| thiram | 16.51±20.26 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| tibrofan | 16.96±6.90 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| tioxidazole | 13.02±1.06 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| Tipranavir | 29.15±2.37 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| tolclofos-methyl | 31.23±19.01 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| Tolfenamic Acid | 14.81±4.38 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| tolvaptan | 17.41±2.00 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| tribromosalan | 0.55±0.36 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| tributyltetradecylphosphonium chloride | 7.66±0.50 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| tributyltin benzoate | 5.33±4.70 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| tributyltin chloride | 8.95±1.03 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| tributyltin methacrylate | 12.76±2.67 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| triclabendazole | 15.55±2.52 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| triclocarban | 0.17±0.10 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| triclosan | 15.17±13.52 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| triethyltin bromide | 0.56±0.21 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| trifluralin | 32.62±23.13 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| trihexyltetradecylphosphonium bromide | 18.82±4.25 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| trihexyltetradecylphosphonium chloride | 30.31±8.97 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| trihexyltetradecylphosphonium dicyanamide | 31.02±11.67 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| triphenyl phosphate | 28.93±9.26 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| triphenylethylene | 15.24±11.48 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| triphenyltin acetate | 24.13±10.14 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| triphenyltin fluoride | 6.17±2.51 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| triphenyltin hydroxide | 14.83±5.12 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| tris(2,3-dibromopropyl) phosphate | 43.95±10.68 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| Tyrothricin | 0.66±0.39 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| vatalanib | 20.73±14.69 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| Verteporfin | 21.83±7.79 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| zafirlukast | 3.43±1.47 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| zearalenone | 21.97±1.79 | rat | hepatocytes | MMP assay | decrease | Positive | IC50 | 163 | |
| glyceraldehyde 3-phosphate | 2.5mM | decrease | Positive | 162 | |||||
| dihydroxyacetone phosphate | decrease | Positive | 162 | ||||||
| Bafilomycin A1 | male Wistar rats | liver mitochondria | affect | Positive | 199 | ||||
| Valinomycin | affect | Positive | 201 | ||||||
| gramicidin | affect | Positive | 201 | ||||||
| Nigericin | affect | Positive | 201 | ||||||
| monensin | affect | Positive | 201 | ||||||
| dianemycin | affect | Positive | 201 | ||||||
| A23187 | affect | Positive | 201 | ||||||
| ionomycin | affect | Positive | 201 | ||||||
| X-537A | affect | Positive | 201 | ||||||
| ionomycin | rat | liver mitochondria | Efflux of mitochondrial Mg2+ was determined by dual wavelength spectroscopy in the presence of 100 PM Eriochrome Blue SE, an indicating dye for free Mg | affect | Positive | 202 | |||
| A23187 | affect | Positive | 203 | ||||||
| acylindolones | affect | Positive | 204 | ||||||
| acylindolones | increase | Positive | 204 | ||||||
| toxoflavin | rat | liver mitochondria | RST assay( Respiratory Screening Technology)-measurement of oxygen consumption in isolated mitochondria using a phosphorescent oxygen-sensitive probe A65N-1 | increase | Positive | 204 | |||
| tesimide | rat | liver mitochondria | RST assay( Respiratory Screening Technology)-measurement of oxygen consumption in isolated mitochondria using a phosphorescent oxygen-sensitive probe A65N-1 | increase | Positive | 204 | |||
| Menadione | rat | liver mitochondria | RST assay( Respiratory Screening Technology)-measurement of oxygen consumption in isolated mitochondria using a phosphorescent oxygen-sensitive probe A65N-1 | increase | Positive | 204 | |||
| Entacapone | rat | liver mitochondria | RST assay( Respiratory Screening Technology)-measurement of oxygen consumption in isolated mitochondria using a phosphorescent oxygen-sensitive probe A65N-1 | affect | Positive | 204 | |||
| Tolcapone | rat | liver mitochondria | RST assay( Respiratory Screening Technology)-measurement of oxygen consumption in isolated mitochondria using a phosphorescent oxygen-sensitive probe A65N-1 | affect | Positive | 204 | |||
| 2,4-dinitrophenol | rat | liver mitochondria | RST assay( Respiratory Screening Technology)-measurement of oxygen consumption in isolated mitochondria using a phosphorescent oxygen-sensitive probe A65N-1 | affect | Positive | 204 | |||
| Anthranilic acid | rat | liver mitochondria | RST assay( Respiratory Screening Technology)-measurement of oxygen consumption in isolated mitochondria using a phosphorescent oxygen-sensitive probe A65N-1 | affect | Positive | 204 | |||
| Fluoromethylsulphonanilide | rat | liver mitochondria | RST assay( Respiratory Screening Technology)-measurement of oxygen consumption in isolated mitochondria using a phosphorescent oxygen-sensitive probe A65N-1 | affect | Positive | 204 | |||
| Nitrophenol | rat | liver mitochondria | RST assay( Respiratory Screening Technology)-measurement of oxygen consumption in isolated mitochondria using a phosphorescent oxygen-sensitive probe A65N-1 | affect | Positive | 204 | |||
| Nitrosulphonanilide | rat | liver mitochondria | RST assay( Respiratory Screening Technology)-measurement of oxygen consumption in isolated mitochondria using a phosphorescent oxygen-sensitive probe A65N-1 | affect | Positive | 204 | |||
| Phenylhydrazone | rat | liver mitochondria | RST assay( Respiratory Screening Technology)-measurement of oxygen consumption in isolated mitochondria using a phosphorescent oxygen-sensitive probe A65N-1 | affect | Positive | 204 | |||
| Salicylic acid | rat | liver mitochondria | RST assay( Respiratory Screening Technology)-measurement of oxygen consumption in isolated mitochondria using a phosphorescent oxygen-sensitive probe A65N-1 | affect | Positive | 204 | |||
| Thiadiazinedione | rat | liver mitochondria | RST assay( Respiratory Screening Technology)-measurement of oxygen consumption in isolated mitochondria using a phosphorescent oxygen-sensitive probe A65N-1 | affect | Positive | 204 | |||
| Thiazolinedione | rat | liver mitochondria | RST assay( Respiratory Screening Technology)-measurement of oxygen consumption in isolated mitochondria using a phosphorescent oxygen-sensitive probe A65N-1 | affect | Positive | 204 | |||
| Hydronaphthoquinone | rat | liver mitochondria | RST assay( Respiratory Screening Technology)-measurement of oxygen consumption in isolated mitochondria using a phosphorescent oxygen-sensitive probe A65N-1 | affect | Positive | 204 | |||
| Naphthoquinone | rat | liver mitochondria | RST assay( Respiratory Screening Technology)-measurement of oxygen consumption in isolated mitochondria using a phosphorescent oxygen-sensitive probe A65N-1 | affect | Positive | 204 | |||
| 2‐Anilinobenzoic acid | affect | Positive | 223 | ||||||
| 2‐(Dialkylamino)‐N‐(2,6‐dimethylphenylacetamide | affect | Positive | 223 | ||||||
| Perfluorinated carboxylic acid | affect | Positive | 223 | ||||||
| Perfluorinated sulfonamide | affect | Positive | 223 | ||||||
| Hydroxynaphthoquinones | Positive | 204 | |||||||
| Naphthoquinone | Positive | 204 | |||||||
| Anthracene‐9,10‐diones | Positive | 223 | |||||||
| Quinones | Positive | 224 | |||||||
| Troglitazone | 10 µM | 6hr | type 2 diabetes mellitus model rat | primary hepatocytes or isolated mitochondria | The loss of mitochondrial calcein and Hoechst 33342 nuclear fluorescence using a fluorescence microscope as an indicator of MPT for rat primary hepatocyte . Mitochondrial swelling as an indicator of MPT for isolated mitochondria. | Positive | 225 | ||
| CCCP | 1e-6M | bovine | frozen beef heart mitochondria | Succinate oxidation was measured manometrically in a Warburg apparatus. Oxidation of B-hydroxy- butyrate was determined by colorlmetric assay of acetoacetate (4). Glucose-6-phosphate formed was assayed spectrophotometrically by the reduction of TPN in the presence of glucose-6-phosphate dehydrogenase. | increase | Positive | 220 | ||
| 2,4-dinitrophenol | 1.6e-6M | Mitochondria from several sources: mouse liver, rat liver, beef heart, | delta 02, delta G-6-P, P/O (with Succinate) | increase | Positive | 221 | |||
| 2,4-dinitrophenol | 0.002M | phosphorylating particles from Alcaligenes faecalis contain a coupling enzyme or enzymes bound to the DPNH oxidase particles by magnesium ion and a specific oligoribonucleotide | increase | Positive | 222 | ||||
| Indomethacin | rat | heart | Positive | 197 | |||||
| Diclofenac | rat | heart | Positive | 197 | |||||
| Nimesulide | affect | Positive | 197 | ||||||
| Nimesulide | Positive | 197 | |||||||
| Nimesulide | Positive | 197 | |||||||
| Meloxicam | Positive | 197 | |||||||
| Indomethacin | Positive | 197 | |||||||
| Indomethacin | Positive | 197 | |||||||
| Diclofenac | Positive | 197 | |||||||
| Lidocaine | Positive | 197 | |||||||
| Cyclosporin A | inhibit | Positive | 248 | ||||||
| Pentachlorophenol | Positive | 253 | |||||||
| Doxorubicin | Positive | 278 | |||||||
| Isoniazid | Positive | 278 | |||||||
| Gentamicin | Positive | 278 | |||||||
| Menadione | Positive | 278 | |||||||
| tetracyclines | Positive | 278 | |||||||
| Ibuprofen | Positive | 278 | |||||||
| pirprofen | Positive | 278 | |||||||
| Flufenamic Acid | Positive | 278 | |||||||
| Diflunisal | Positive | 278 | |||||||
| Tolfenamic Acid | Positive | 278 | |||||||
| Diclofenac | Positive | 278 | |||||||
| Indomethacin | Positive | 278 | |||||||
| Naproxen | Positive | 278 | |||||||
| propranolol | Positive | 278 | |||||||
| amineptine | Positive | 278 | |||||||
| Tianeptine | Positive | 278 | |||||||
| pentamidine | Positive | 278 | |||||||
| imipramine | Positive | 278 | |||||||
| Chlorpromazine | Positive | 278 | |||||||
| Bupivacaine | Positive | 278 | |||||||
| buprenorphine | Positive | 278 | |||||||
| Perhexiline | Positive | 278 | |||||||
| Chloroquine | Positive | 278 | |||||||
| Fluoxetine | Positive | 278 | |||||||
| Propofol | Positive | 278 | |||||||
| Acetylsalicylic acid | Positive | 278 | |||||||
| Tamoxifen | Positive | 278 | |||||||
| Amiodarone | Positive | 278 | |||||||
| Tolcapone | Positive | 278 | |||||||
| JW47 | 10nM | rat | liver mitochondria | Assess Ca2+-mediated PT pore formation by Calcium Retention Capacity Assay (Fluo-5N fluorescence was measured in the extramitochondrial solution following repeated additions of Ca2+) | inhibit | Positive | half-maximal inhibition | 324 | |
| Cyclosporin A | 40nM | rat | liver mitochondria | Assess Ca2+-mediated PT pore formation by Calcium Retention Capacity Assay (Fluo-5N fluorescence was measured in the extramitochondrial solution following repeated additions of Ca2+) | inhibit | Positive | half-maximal inhibition | 324 | |
| JW47 | 1 μM | rat | rat cortical neurons and isolated rat liver mitochondria | mitochondrial membrane potential was measured in tetramethylrhodamine methyl ester (TMRM)-loaded neurons using ImageXpress MicroXL, and in rhodamine-123 loaded isolated mitochondria using a fluorescent plate reader | Positive | 324 | |||
| Clofarabine | Positive | 284 | |||||||
| Cinnamic anilides | swellilng assay, Rhodamine 123 (Rh123) uptake assay, Calcium retention capacity assay | induce | Positive | 290 | |||||
| Dequalinium Chloride | 1 hr | Ishikawa and Caco-2 | JC-10 fluorescent dye | decrease | Positive | 299 | |||
| Cisplatin | 1 or 3 hr | Ishikawa and Caco-2 | JC-10 fluorescent dye | decrease | Positive | 299 | |||
| Cadmium | 50 μM | 3-24hr | rat | PC12 cells (neuron-like ) | flow cytometry after staining the cells with the lipophilic cationic probe TMRM | decrease | Positive | 300 | |
| Mercury | 50 μM | rat | PC12 cells (neuron-like ) | flow cytometry after staining the cells with the lipophilic cationic probe TMRM | decrease | Positive | 300 | ||
| dodecyl gallate | 2.13 ± 0.2 μM | 72hr | Epimastigote forms of Trypanosoma cruzi of Y strain, | measured by flow cytometry using JC-1 dye (BD MitoScreen kit) | decrease | Positive | IC50 | 305 | |
| Benznidazole | 34μM | Epimastigote forms of Trypanosoma cruzi of Y strain, | measured by flow cytometry using JC-1 dye (BD MitoScreen kit) | decrease | Positive | IC50 | 305 | ||
| P110 | 1 µM | mouse | isolated liver mitochondria | TMRM | enhance | Positive | 310 | ||
| Cisplatin | U2OS | release of Smac m cherry(IMS-RP probe is a non-functional variant of mitochondrial protein Smac - mCherry fusion protein that acts as an indicator of mitochondrial permeabilization in live cells) | induce | Positive | 313 | ||||
| Gentamicin | 2.5 mM | rat | isolated rat liver (and kidney) mitochondria | MtMP was investigated with the use of safranin, a biological stain with an excitation wavelength of 495 nm and an emission wavelength of 587 nm. | reduce | Positive | 316 | ||
| Gentamicin | mouse | Mouse Cochlear Culture Sensory Hair Cells | Rhodamine-123 | reduce | Positive | 316 | |||
| Berberine | 25 μM | 6, 24 hr | K1735-M2 mouse melanoma cells | TMRM | decrease | Positive | 327 | ||
| Berberine | 31.2 nmol/mg | isolated rat muscle mitochondria | evaluate mitochondrial calcium loading capacity using the fluorescence probe Calcium Green 5N | induce | Positive | 327 | |||
| Acetaminophen | > 200 µM | 30 mins | mouse | liver mitochondria | Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) | decrease | Positive | EC20 | 36 |
| Acetylsalicylic acid | 335.5 µM | 30 mins | mouse | liver mitochondria | Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) | decrease | Positive | EC20 | 36 |
| alpidem | 83.7 µM | 30 mins | mouse | liver mitochondria | Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) | decrease | Positive | EC20 | 36 |
| Amantadine | 261.2 µM | 30 mins | mouse | liver mitochondria | Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) | decrease | Positive | EC20 | 36 |
| Ambroxol | > 200 µM | 30 mins | mouse | liver mitochondria | Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) | decrease | Positive | EC20 | 36 |
| Amiodarone | 2.6 µM | 30 mins | mouse | liver mitochondria | Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) | decrease | Positive | EC20 | 36 |
| Amoxicillin | > 400 µM | 30 mins | mouse | liver mitochondria | Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) | decrease | Positive | EC20 | 36 |
| Ampicillin | > 400 µM | 30 mins | mouse | liver mitochondria | Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) | decrease | Positive | EC20 | 36 |
| Antipyrine | 300 µM | 30 mins | mouse | liver mitochondria | Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) | decrease | Positive | EC20 | 36 |
| Arsenic trioxide | 237.9 µM | 30 mins | mouse | liver mitochondria | Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) | decrease | Positive | EC20 | 36 |
| Biotin | 4.3 µM | 30 mins | mouse | liver mitochondria | Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) | decrease | Positive | EC20 | 36 |
| lumiracoxib | > 400 µM | 30 mins | mouse | liver mitochondria | Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) | decrease | Positive | EC20 | 36 |
| bisacodyl | 312.4 µM | 30 mins | mouse | liver mitochondria | Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) | decrease | Positive | EC20 | 36 |
| estradiol acetate | > 200 µM | 30 mins | mouse | liver mitochondria | Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) | decrease | Positive | EC20 | 36 |
| Bupivacaine | 258.2 µM | 30 mins | mouse | liver mitochondria | Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) | decrease | Positive | EC20 | 36 |
| Busulfan | 483.1 µM | 30 mins | mouse | liver mitochondria | Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) | decrease | Positive | EC20 | 36 |
| Butein | > 200 µM | 30 mins | mouse | liver mitochondria | Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) | decrease | Positive | EC20 | 36 |
| Caffeine | > 400 µM | 30 mins | mouse | liver mitochondria | Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) | decrease | Positive | EC20 | 36 |
| Capsaicin | 275 µM | 30 mins | mouse | liver mitochondria | Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) | decrease | Positive | EC20 | 36 |
| Carbamazepine | 66.9 µM | 30 mins | mouse | liver mitochondria | Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) | decrease | Positive | EC20 | 36 |
| Cefixime | > 400 µM | 30 mins | mouse | liver mitochondria | Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) | decrease | Positive | EC20 | 36 |
| Chlorambucil | > 200 µM | 30 mins | mouse | liver mitochondria | Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) | decrease | Positive | EC20 | 36 |
| Ciprofloxacin | > 400 µM | 30 mins | mouse | liver mitochondria | Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) | decrease | Positive | EC20 | 36 |
| Clodronate | > 400 µM | 30 mins | mouse | liver mitochondria | Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) | decrease | Positive | EC20 | 36 |
| Clotrimazole | 23.9 µM | 30 mins | mouse | liver mitochondria | Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) | decrease | Positive | EC20 | 36 |
| curcumin | > 200 µM | 30 mins | mouse | liver mitochondria | Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) | decrease | Positive | EC20 | 36 |
| dexamethasone valerate | > 200 µM | 30 mins | mouse | liver mitochondria | Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) | decrease | Positive | EC20 | 36 |
| Diazoxide | > 200 µM | 30 mins | mouse | liver mitochondria | Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) | decrease | Positive | EC20 | 36 |
| Diclofenac | 137.9 µM | 30 mins | mouse | liver mitochondria | Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) | decrease | Positive | EC20 | 36 |
| Diflunisal | 17.9 µM | 30 mins | mouse | liver mitochondria | Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) | decrease | Positive | EC20 | 36 |
| Doxorubicin | 8.9 µM | 30 mins | mouse | liver mitochondria | Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) | decrease | Positive | EC20 | 36 |
| erlotinib | 195.9 µM | 30 mins | mouse | liver mitochondria | Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) | decrease | Positive | EC20 | 36 |
| Fluconazole | 512.7 µM | 30 mins | mouse | liver mitochondria | Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) | decrease | Positive | EC20 | 36 |
| Flufenamic Acid | 42.5 µM | 30 mins | mouse | liver mitochondria | Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) | decrease | Positive | EC20 | 36 |
| Flutamide | 27 µM | 30 mins | mouse | liver mitochondria | Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) | decrease | Positive | EC20 | 36 |
| gefitinib | 9.6 µM | 30 mins | mouse | liver mitochondria | Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) | decrease | Positive | EC20 | 36 |
| genistein | 150.6 µM | 30 mins | mouse | liver mitochondria | Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) | decrease | Positive | EC20 | 36 |
| Glimepiride | 94.6 µM | 30 mins | mouse | liver mitochondria | Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) | decrease | Positive | EC20 | 36 |
| Gossypol | 1 µM | 30 mins | mouse | liver mitochondria | Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) | decrease | Positive | EC20 | 36 |
| Ibuprofen | 355.9 µM | 30 mins | mouse | liver mitochondria | Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) | decrease | Positive | EC20 | 36 |
| Imatinib | 25.7 µM | 30 mins | mouse | liver mitochondria | Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) | decrease | Positive | EC20 | 36 |
| imipramine | 74.8 µM | 30 mins | mouse | liver mitochondria | Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) | decrease | Positive | EC20 | 36 |
| Indomethacin | 443.2 µM | 30 mins | mouse | liver mitochondria | Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) | decrease | Positive | EC20 | 36 |
| Isoniazid | 504.6 µM | 30 mins | mouse | liver mitochondria | Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) | decrease | Positive | EC20 | 36 |
| Ketoconazole | 243 µM | 30 mins | mouse | liver mitochondria | Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) | decrease | Positive | EC20 | 36 |
| Lamivudine | 347.2 µM | 30 mins | mouse | liver mitochondria | Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) | decrease | Positive | EC20 | 36 |
| Lidocaine | 339.5 µM | 30 mins | mouse | liver mitochondria | Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) | decrease | Positive | EC20 | 36 |
| Lonidamine | 138.1 µM | 30 mins | mouse | liver mitochondria | Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) | decrease | Positive | EC20 | 36 |
| lovastatin | 43.6 µM | 30 mins | mouse | liver mitochondria | Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) | decrease | Positive | EC20 | 36 |
| lumiracoxib | 148.8 µM | 30 mins | mouse | liver mitochondria | Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) | decrease | Positive | EC20 | 36 |
| Manganese | > 800 µM | 30 mins | mouse | liver mitochondria | Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) | decrease | Positive | EC20 | 36 |
| Mefenamic acid | 49.7 µM | 30 mins | mouse | liver mitochondria | Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) | decrease | Positive | EC20 | 36 |
| Metformin | 388.4 µM | 30 mins | mouse | liver mitochondria | Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) | decrease | Positive | EC20 | 36 |
| Mitomycin | > 200 µM | 30 mins | mouse | liver mitochondria | Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) | decrease | Positive | EC20 | 36 |
| Mitoxantrone | 7 µM | 30 mins | mouse | liver mitochondria | Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) | decrease | Positive | EC20 | 36 |
| Nicotine | > 400 µM | 30 mins | mouse | liver mitochondria | Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) | decrease | Positive | EC20 | 36 |
| nifuroxazide | 388.2 µM | 30 mins | mouse | liver mitochondria | Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) | decrease | Positive | EC20 | 36 |
| Nimesulide | 10.1 µM | 30 mins | mouse | liver mitochondria | Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) | decrease | Positive | EC20 | 36 |
| Nitrofurantoin | 442.5 µM | 30 mins | mouse | liver mitochondria | Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) | decrease | Positive | EC20 | 36 |
| Perhexiline | 3.2 µM | 30 mins | mouse | liver mitochondria | Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) | decrease | Positive | EC20 | 36 |
| Piroxicam | 101.7 µM | 30 mins | mouse | liver mitochondria | Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) | decrease | Positive | EC20 | 36 |
| pravastatin | > 200 µM | 30 mins | mouse | liver mitochondria | Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) | decrease | Positive | EC20 | 36 |
| propylparaben | 162.8 µM | 30 mins | mouse | liver mitochondria | Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) | decrease | Positive | EC20 | 36 |
| Pyrazinamide | > 400 µM | 30 mins | mouse | liver mitochondria | Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) | decrease | Positive | EC20 | 36 |
| resveratrol | 395.4 µM | 30 mins | mouse | liver mitochondria | Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) | decrease | Positive | EC20 | 36 |
| rifampicin | > 800 µM | 30 mins | mouse | liver mitochondria | Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) | decrease | Positive | EC20 | 36 |
| ritonavir | 24.8 µM | 30 mins | mouse | liver mitochondria | Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) | decrease | Positive | EC20 | 36 |
| Salicylic acid | 304.3 µM | 30 mins | mouse | liver mitochondria | Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) | decrease | Positive | EC20 | 36 |
| Simvastatin | 76.5 µM | 30 mins | mouse | liver mitochondria | Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) | decrease | Positive | EC20 | 36 |
| sorafenib | 0.5 µM | 30 mins | mouse | liver mitochondria | Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) | decrease | Positive | EC20 | 36 |
| Sulindac | > 200 µM | 30 mins | mouse | liver mitochondria | Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) | decrease | Positive | EC20 | 36 |
| Tamoxifen | 2.9 µM | 30 mins | mouse | liver mitochondria | Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) | decrease | Positive | EC20 | 36 |
| Tolcapone | 3.9 µM | 30 mins | mouse | liver mitochondria | Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) | decrease | Positive | EC20 | 36 |
| Tolfenamic Acid | 263.8 µM | 30 mins | mouse | liver mitochondria | Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) | decrease | Positive | EC20 | 36 |
| Troglitazone | 3.4 µM | 30 mins | mouse | liver mitochondria | Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) | decrease | Positive | EC20 | 36 |
| Valproic Acid | 267.2 µM | 30 mins | mouse | liver mitochondria | Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) | decrease | Positive | EC20 | 36 |
| Zidovudine | 416.1 µM | 30 mins | mouse | liver mitochondria | Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) | decrease | Positive | EC20 | 36 |
| Amiodarone | 10 µM | 1 hour | Human | HepG2 | High-content screening assay | Increase | Positive | MEC | 306 |
| Chlorpromazine | >100 µM | 1 hour | Human | HepG2 | High-content screening assay | Affect | Positive | MEC | 306 |
| imipramine | 50 µM | 1 hour | Human | HepG2 | High-content screening assay | Decrease | Positive | MEC | 306 |
| Maprotiline | 5 µM | 1 hour | Human | HepG2 | High-content screening assay | Decrease | Positive | MEC | 306 |
| Rotenone | 5 µM | 1 hour | Human | HepG2 | High-content screening assay | Decrease | Positive | MEC | 306 |
| Tamoxifen | 100 µM | 1 hour | Human | HepG2 | High-content screening assay | Decrease | Positive | MEC | 306 |
| Troglitazone | 5 µM | 1 hour | Human | HepG2 | High-content screening assay | Decrease | Positive | MEC | 306 |
| atorvastatin | 50 µM | 1 hour | Human | HepG2 | High-content screening assay | Decrease | Positive | MEC | 306 |
| Cerivastatin | 10 µM | 1 hour | Human | HepG2 | High-content screening assay | Decrease | Positive | MEC | 306 |
| fluvastatin | 10 µM | 1 hour | Human | HepG2 | High-content screening assay | Decrease | Positive | MEC | 306 |
| lovastatin | 50 µM | 1 hour | Human | HepG2 | High-content screening assay | Decrease | Positive | MEC | 306 |
| Simvastatin | 10 µM | 1 hour | Human | HepG2 | High-content screening assay | Decrease | Positive | MEC | 306 |
| Amiodarone | 50 µM | 1 hour | Human | HepG2 | High-content screening assay | Decrease | Positive | MEC | 306 |
| Amiodarone | 5 µM | 1 hour | Human | HepG2 | High-content screening assay | Increase | Positive | MEC | 306 |
| Chlorpromazine | 100 µM | 1 hour | Human | HepG2 | High-content screening assay | Decrease | Positive | MEC | 306 |
| Cyclosporin A | 5 µM | 1 hour | Human | HepG2 | High-content screening assay | Increase | Positive | MEC | 306 |
| imipramine | 50 µM | 1 hour | Human | HepG2 | High-content screening assay | Decrease | Positive | MEC | 306 |
| Maprotiline | 5 µM | 1 hour | Human | HepG2 | High-content screening assay | Decrease | Positive | MEC | 306 |
| Rotenone | 5 µM | 1 hour | Human | HepG2 | High-content screening assay | Decrease | Positive | MEC | 306 |
| Tamoxifen | 100 µM | 1 hour | Human | HepG2 | High-content screening assay | Decrease | Positive | MEC | 306 |
| Troglitazone | 10 µM | 1 hour | Human | HepG2 | High-content screening assay | Decrease | Positive | MEC | 306 |
| atorvastatin | 100 µM | 1 hour | Human | HepG2 | High-content screening assay | Increase | Positive | MEC | 306 |
| Cerivastatin | 50 µM | 1 hour | Human | HepG2 | High-content screening assay | Decrease | Positive | MEC | 306 |
| lovastatin | 100 µM | 1 hour | Human | HepG2 | High-content screening assay | Decrease | Positive | MEC | 306 |
| Simvastatin | 50 µM | 1 hour | Human | HepG2 | High-content screening assay | Decrease | Positive | MEC | 306 |
| tetracyclines | decrease | Positive | 307 | ||||||
| Clozapine | Increase | Positive | 307 | ||||||
| Flufenamic Acid | 129 | 24hr | rat | hepatocytes | tetramethylrhodamine ethyl ester (TMRE) | decrease | Positive | AC50 (μM) | 40 |
| Tolfenamic Acid | 122 | 24hr | rat | hepatocytes | tetramethylrhodamine ethyl ester (TMRE) | decrease | Positive | AC50 (μM) | 40 |
| Mefenamic acid | 376 | 24hr | rat | hepatocytes | tetramethylrhodamine ethyl ester (TMRE) | decrease | Positive | AC50 (μM) | 40 |
| Meloxicam | 382 | 24hr | rat | hepatocytes | tetramethylrhodamine ethyl ester (TMRE) | decrease | Positive | AC50 (μM) | 40 |
| Sudoxicam | 487 | 24hr | rat | hepatocytes | tetramethylrhodamine ethyl ester (TMRE) | decrease | Positive | AC50 (μM) | 40 |
| Piroxicam | 796 | 24hr | rat | hepatocytes | tetramethylrhodamine ethyl ester (TMRE) | decrease | Positive | AC50 (μM) | 40 |
| Diflunisal | 115 | 24hr | rat | hepatocytes | tetramethylrhodamine ethyl ester (TMRE) | decrease | Positive | AC50 (μM) | 40 |
| Diclofenac | 487 | 24hr | rat | hepatocytes | tetramethylrhodamine ethyl ester (TMRE) | decrease | Positive | AC50 (μM) | 40 |
| Sulindac sulfide | 28 | 24hr | rat | hepatocytes | tetramethylrhodamine ethyl ester (TMRE) | decrease | Positive | AC50 (μM) | 40 |
| Nimesulide | 30 | 24hr | rat | hepatocytes | tetramethylrhodamine ethyl ester (TMRE) | decrease | Positive | AC50 (μM) | 40 |
| Cyazofamid | 50µM | permeabilized LUHMES cells | Assessment of the function of individual mitochondrial complexes using Agilent Seahorse XFe24 | Positive | EC25(NA) [Glc/Gal] | 326 | |||
| Troglitazone | 10–75 μM | male CD-1 mice | isolated liver mitochondria | Mitochondrial swelling as the indicator of mitochondrial permeability transition (MPT) was estimated from the decrease in absorbance at 540 nm. | induce | Positive | 331 | ||
| Ciglitazone | 10–75 μM | male CD-1 mice | isolated liver mitochondria | Mitochondrial swelling as the indicator of mitochondrial permeability transition (MPT) was estimated from the decrease in absorbance at 540 nm. | induce | Positive | 331 | ||
| Troglitazone | 10–50 μM | 3min | male CD-1 mice | isolated liver mitochondria | The electrical transmembrane potential of mitochondria was monitored spectrophotometrically with the cationic dye, rhodamine 123, and monitored at the 505/535 nm. | decrease | Positive | p < 0.05, significantly different from the control | 331 |
| Ciglitazone | 10–50 μM | 3min | male CD-1 mice | isolated liver mitochondria | The electrical transmembrane potential of mitochondria was monitored spectrophotometrically with the cationic dye, rhodamine 123, and monitored at the 505/535 nm. | decrease | Positive | p < 0.05, significantly different from the control | 331 |
| Pioglitazone | 50 μM | 3min | male CD-1 mice | isolated liver mitochondria | The electrical transmembrane potential of mitochondria was monitored spectrophotometrically with the cationic dye, rhodamine 123, and monitored at the 505/535 nm. | decrease | Positive | p < 0.05, significantly different from the control | 331 |
| Troglitazone | 10 µM | 6hr | ZDF fa/fa rat vs ZDF lean rat | hepatocytes | Co2+-calcein assays; MPT pore opening was determined by measuring intensity of calcein fluorescence in the mitochondria quenched by cobalt and normalizing cell number of hoechst33342. | induce | Positive | significantly different from ZDF lean rats (p < 0.05) | 225 |
| Troglitazone | 10-50 µM | ZDF fa/fa rat & ZDF lean rat | isolated liver mitochondria | The transmembrane potential of the mitochondria was monitored spectrophotometrically using rhodamine-123. | decrease | Positive | significantly different from control group (p < 0.05) | 225 | |
| Pioglitazone | 25-50 µM | ZDF fa/fa rat & ZDF lean rat | isolated liver mitochondria | The transmembrane potential of the mitochondria was monitored spectrophotometrically using rhodamine-123. | decrease | Positive | significantly different from control group (p < 0.05) | 225 | |
| Phenformin | 100-300 μM | ZDF fa/fa rat & ZDF lean rat | isolated liver mitochondria | The transmembrane potential of the mitochondria was monitored spectrophotometrically using rhodamine-123. | decrease | Positive | significantly different from control group (p < 0.05) | 225 | |
| Troglitazone | >25 µM | 30min | HepG2 cells | JC1 | decrease | Positive | 332 | ||
| Troglitazone | 100 µM | 5min | HepG2 cells | Tetramethylrhodamine methyl ester (TMRE) | decrease | Positive | 330 | ||
| Troglitazone | 61.9 µM | 3hr | HepG2 cells | stained with a Mitotracker red dye, and then fixed with paraformaldehyde | decrease | Positive | IC50 | 330 | |
F0101. depolarization
F0102. delay in initiation of deloparization
F0103. hyperpolarization
F0104. permeabilization
F0105. uncoupling
F0106. Ionophore
F0107. protonophore
F0108. membrane potential
F0109. redox cycling
F0110. proton conductivity
F010101. calcium-dependent
F010401. Opening of permeability transition pore (PTP)
F010501. Nonprotonophoric Uncouplers
F010502. protonophoric uncoupling
F010503. electrophoretic uncoupling
F010601. transport of protons and charge (proton ionophore)
F010602. transport of charge but not protons
F010603. transport of protons but not charge (K+)
F010604. transport of protons but not charge (Na+)
F010605. transport of protons but not charge (Ca2+ or Mg2+)
F010606. transport of protons but not charge (Cations)
F010701. associate with uncoupling
F011001. proton conductivity by F0
F0102. delay in initiation of deloparization
F0103. hyperpolarization
F0104. permeabilization
F0105. uncoupling
F0106. Ionophore
F0107. protonophore
F0108. membrane potential
F0109. redox cycling
F0110. proton conductivity
F010101. calcium-dependent
F010401. Opening of permeability transition pore (PTP)
F010501. Nonprotonophoric Uncouplers
F010502. protonophoric uncoupling
F010503. electrophoretic uncoupling
F010601. transport of protons and charge (proton ionophore)
F010602. transport of charge but not protons
F010603. transport of protons but not charge (K+)
F010604. transport of protons but not charge (Na+)
F010605. transport of protons but not charge (Ca2+ or Mg2+)
F010606. transport of protons but not charge (Cations)
F010701. associate with uncoupling
F011001. proton conductivity by F0